

CURRICULUM VITAE

Name: PROFESSOR SIR ALEXANDER FRED MARKHAM

Date of Birth: 30 November 1950

Place of Birth: Ashton-under-Lyne, ENGLAND

Qualifications: Scientific: BSc, PhD, DSc, CChem, FRSC,
[HonDMedSci, HonDUniv, HonDSc].
Clinical: MBBS, FRCP, FRCPath, FMedSci,
[HonDMed, HonDUniv, Kt].

Affiliations/Professional Experience

1968 - 1971 BSc in Chemistry, University of Birmingham.

1971 - 1974 PhD in Organic Chemistry, University of Birmingham.
Supervisor: Professor A S Jones.

1992 DSc in Chemistry, University of Birmingham.

1974 - 1976 Royal Society Research Fellow,
Osaka University, Japan, with Professor M Ikehara.

1976 - 1977 Cancer Research Campaign Research Fellow,
Imperial College of Science and Technology,
University of London, with Professor Sir Derek Barton FRS, NL.

1977 - 1979 G D Searle Pharmaceuticals, High Wycombe, Bucks.

1979 - 1990 ICI (now AstraZeneca) Pharmaceuticals/Diagnostics, Cheshire.
Research Scientist/Group Leader/Research Manager/Medical Director,
[Visiting Professor, St. Mary's Hospital Medical School, London].

1980 - 1986 St Mary's Hospital Medical School, University of London.
MBBS [Foulkes Foundation Fellow].

1990 - 1992 Nuffield Department of Clinical Medicine, University of Oxford,
John Radcliffe Hospital, Oxford, OX3 9DU.

1992 - Date Professor of Medicine, University of Leeds.
Hon Consultant Physician, Leeds Teaching Hospitals NHS Trust.

1992 - 2003 Director, Molecular Medicine Unit, University of Leeds.

2003 - 2007 Chief Executive, Cancer Research UK.

2007 - 2013 Senior Responsible Owner, NIHR Research Capability Programme.

Visiting Research

1978, 1979

MRC Laboratory of Molecular Biology, Cambridge, CB2 2QH.
Collaboration with Drs R. Sheppard and M. J. Gait.

1982, 1984

Harvard University Medical School
The Children's Hospital Medical Centre, Boston, MA 02115, USA.
Collaboration with Professor S. H. Orkin.

Present Appointments

West Riding Professor of Medicine, University of Leeds.
Honorary Consultant Physician, Leeds Teaching Hospitals NHS Trust.

Senior Responsible Owner, NIHR Research Capability Programme.
Senior Medical Advisor, Cancer Research UK.
Chairman, Scientific Strategy Committee and Trustee, Arthritis Research UK.

Additional Information

General Medical Council Registration Number 3066166
Date of Full Registration: 11th August 1986.
Medical Insurance: Medical Defence Union 08/194929A
USA Medical Qualification: ECFMG Certification Number: 401-065-8

Fellow of the Royal College of Physicians, London.
Fellow of the Royal College of Pathologists.
Fellow of the Royal Society of Chemistry.
Fellow of the Academy of Medical Sciences.
Knight Bachelor, New Year Honours 2008.
Honorary Doctorates: Universities of Manchester, Leeds, Stirling, Keele and York.

Professional Societies

- Association of Physicians of Great Britain and Ireland
(Honorary Membership, 2008; Osler Lecturer, 1995; Helen Rollason Lecturer, Association of Surgeons of Great Britain and Ireland, 2009)
- Association of Clinical Professors of Medicine
- Royal College of Physicians
- Royal College of Pathologists
- Royal Society of Chemistry
- American Society of Human Genetics
- American Association for Cancer Research
- American Society of Clinical Oncology
- British Society of Gastroenterology (Honorary Membership 2010)
- British Society of Human Genetics
- Academy of Medical Sciences (Forum Lecturer, 2004)

Current Administrative Responsibilities

UK Government

- Department of Health, Senior Responsible Owner and Board Chairman, NIHR/NHS Connecting for Health, Research Capability Programme, 2008-date.
- HEFCE, Chairman Clinical Medicine Research Excellence Framework (REF) Impact Pilot Panel, 2009-date.
- National Cancer Intelligence Network Steering Group Chairman, 2006-date.
- NIHR Senior Investigators Appointment Panel Member, 2007-2010; Chairman 2011-2014.
- Department of Health, Cancer Reform Strategy Advisory Board Member, 2007-date; Clinical Outcomes in Cancer Group Chairman, 2007-date.
- NHS National Information Reporting Service, Programme Board Member (with NHS Connecting for Health and the Information Centre for Health and Social Care), 2008-date.
- NHS Information Centre for Health and Social Care. General Practice Extraction Service Project Board Member, 2008-date.
- Department of Health/MHRA/ABPI, Ministerial Industry Strategy Group Advisory Panel Member, 2006-date.
- NCRI Informatics Initiative, Management Board Chairman, 2003-date.
- OSCHR Therapeutic Capability Clusters Delivery and Oversight Group Member, 2009-date.

Medical Research Council

- International Agency for Research on Cancer (World Health Organisation), UK-nominated Scientific Advisory Board Member, 2008-date.
- MRC Centre for Drug Safety Science, University of Liverpool, Scientific Advisory Board Member, 2009-date.

Other Organisations

- Chairman (elect), the Lister Institute of Preventive Medicine, 2010-date.
- BBSRC: The Genome Analysis Centre, Institute Board Chairman, 2010-date.
- Oxford University Cancer Centre, Board Chairman, 2010-date.
- German Consortium for Translational Cancer Research of the Federal Ministry of Education and Research, Review Panel Member, 2010-date.
- The Oak Foundation (Geneva), Medical Advisory Board Member, 2010-date.
- Arthritis Research UK, Chairman Scientific Strategy Committee and Trustee, 2009-date.
- Sir Jules Thorn Medical Research Trust International Autozygosity Mapping Resource, Steering Group Chairman, 2009-date.
- Academy of Medical Sciences, Clinical Academic Careers Committee Member, 2008-date.
- Deutsche Krebshilfe Program for the Development of Interdisciplinary Oncology Centers of Excellence in Germany, Clinical Advisory Board Member, 2008-date.
- Singapore Government Agency for Science, Technology and Research (A-STAR) Board Member, 2007-date.
- A-STAR Biomedical Research Council Board Member, 2007-date.
- International Union Against Cancer (UICC), Member of the Board of Directors, 2006-date.
- Vice President “QUIT”, the ‘Stop Smoking’ charity, 2004-date.
- Governor, Bradford Grammar School, Yorkshire, 2008-date.
- Foulkes Foundation Scientific Advisory Board Member, 1992-2007; Trustee, 2007-date.
- Daniel Turnberg Trust Panel Member, Academy of Medical Sciences, 2008-date.
- Trustee, Candlelighter’s Trust, Yorkshire Children’s Cancer Charity, 1993-date.
- International Advisory Board Member, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, 2008-date.

Previous Administrative Responsibilities

UK Government

- Office for the Strategic Co-ordination of Health Research (OSCHR), Translational Medicine Board Chairman. H.M. Treasury, Departments of Health / Innovation, Universities and Skills, 2007- 2010.
- Department of Health, National Programme for Information Technology (NPfIT) Board Member, 2007-2010.
- UK Clinical Research Collaboration Board Member, 2004-2007.
- National Institute for Health Research Advisory Board Member, 2006-2007.
- Department of Innovation, Universities and Skills, Government Office for Science; Science Review of the Department of Health, Steering Panel Member, 2007-2008.
- Department of Health, Expert Scientific Group on Phase 1 Clinical Trials, Member 2006. [The Northwick Park Enquiry].
- Department of Health, Ministerial Advisory Group on the Operation of NHS Research Ethics Committees, Member, 2004-2005. [Lord Warner Report].
- Department of Health/HEFCE, National Clinician Scientist Awards Panel Chairman, 2001-2003.
- Department of Health, Gene Therapy Advisory Committee Member, 2000-2006.
- MHRA, Committee on Safety of Medicines, Biologicals Sub-Committee, 2002-2006.
- Department of Health, Advisory Group for Genetics Research, 2003-2007.
- EPSRC Metrology for Life Sciences, Assessment Panel Member, 2000-2004.
- EPSRC Engineering Responsive Mode Advisory Panel for Healthcare, Member, 2002-2004.
- Office of Science and Technology, Technology Foresight Programme: Health and Life Sciences Sector Panel Member, 1994-96 and 1999-2000.
- NHS Central Research and Development Committee (CRDC), Standing Group on Health Technology: Population Screening Advisory Panel Member, 1994-2003.
- NHS Central Research and Development Committee (CRDC), National Expert Advisory Group on Genetics Member, 1993-95.
- Department of Health, Advisory Committee on Dangerous Pathogens ad hoc Committee on Gene Therapy, 1997.
- Northern and Yorkshire Regional Health Authority, Biomedical Research Working Group Member, 1995-98.
- Yorkshire Regional Health Authority Locally Organised Research Scheme and Clinical Advances Fund Programme, Expert Working Group Member, 1993-95.

Medical Research Council

- MRC Interim Strategy and Planning Group Member, 2007.
- MRC Training and Career Development Board Member, 2000-2003.
- MRC Clinical Training and Career Development Panel Chairman, 1999-2002.
- MRC Clinical Training and Career Development Panel Member, 1994-1998.
- MRC Scientific Advisory Committee Member, 1997-2003.
- MRC Molecular and Cellular Medicine Board Grants Committee B Member, 1993-1997.
- MRC Special Training Fellowships Panel for Health Services Research Member, 1995-1997.
- MRC “Realising Our Potential Awards” (ROPA) Panel Member, 1995-1997.

- MRC/Wellcome Human Embryo Banking/Human Developmental Biology Resource Working Party Chairman, 1996–2003.
- MRC Animal Embryo Banking Working Party Chairman, 1996-2002.
- MRC/ECACC Cell Bank Working Party Member, 1996-2003.
- MRC Joint Research Equipment Initiative Panel Member, 1998. Chairman, 1999–2003.
- MRC ALSPAC Co-operative Group Member, 1999–2004.
- MRC Advisory Committee on ‘Scientific Advances in Genetics (ACSAG) which impact on the Health Service & Society’ Member, 2000-2003.
- MRC National Stem Cell Bank Advisory Committee Member, 2001-2003.
- MRC “Clinical Applications of Advances in Human Genetics” Co-operative Group, Principal Investigator, 2001-2006.
- MRC Programme Grant, Principal Investigator, 1994-1999.
- MRC Pre-Doctoral Fellowships Panel Chairman, 2002-2004.
- MRC/BBSRC/AMRC Stem Cell Fellowships Panel Chairman, 2003–2005.

Wellcome Trust

- Wellcome Trust Molecular and Cell Panel Chairman, 2003.
- Wellcome Trust Molecular and Cell Panel Member, 2000-2002, Deputy Chairman 2002-03.
- Wellcome Trust Equipment Working Party Member, 1996-1999.
- Wellcome Trust Infrastructure Panel Member, 1997-1999.
- Wellcome Trust/Health Research Board Republic of Ireland, “New Blood” Fellowships in Medical Science Panel Chairman, 1998-2002.
- Wellcome Trust/Irish Health Research Board, Equipment Awards Panel Member, 2000–2003.
- Wellcome Trust Innovation Awards Committee Member, 1998-2002.
- Wellcome Trust/Joint Infrastructure Fund, “Leeds Centre for Biomolecular Interactions”, Investigator 2001-2006.
- Wellcome Trust/Strategic Research Infrastructure Fund, “Leeds Institute of Molecular Medicine”, Principal Applicant, 2001-2006.

Other Organisations

- Chief Executive, Cancer Research UK, 2003-2007.
- National Cancer Research Institute Chairman, 2003-2006, Board Member 2006-2008.
- Cancer Research UK Clinical Training Panel Chairman, 2007-2009.
- Cancer Research UK Scientific Strategy Advisory Group Chair/Member, 2003-2009.
- American Association for Cancer Research, International Affairs Committee Member, 2004-2009.
- Li Ka Shing Institute of Health Sciences at the Chinese University of Hong Kong, Steering Committee Member, 2007-2010.
- Scientific Advisory Board Member, Weatherall Institute of Molecular Medicine, Oxford, 1999-2009.
- International Advisory Committee Member, Conway Institute of Biomolecular and Biomedical Research, University and Trinity Colleges Dublin, and Royal College of Surgeons of Ireland, 2001-2004.

- International Advisory Board Member, BBSRC/MRC/EPSRC UK Centre for Tissue Engineering, Manchester/Liverpool, 2001-2004.
- Manchester Comprehensive Cancer Research Centre Board Member, 2005-2007.
- University of Sheffield Cancer Research Advisory Board Chair, 2008-2009.
- Quarterly Journal of Medicine, Editorial Board Member 1995-2008.
- Institute for Cancer Research, London. Trustee, 2003-2005.
- Clatterbridge Hospital Liverpool Scientific Advisory Committee Member, 1994-2003.
- ALSPAC (Avon Longitudinal Study of Pregnancy and Childhood) Genetics Advisory Committee Member, 1996-2001.
- Scientific Advisory Committee Member, Yorkshire Cancer Research Campaign, 1993-2000.
- Scientific Advisory Committee Member, Northwest Cancer Research Charity, 1999-2001.
- Research and Development Director, St James's University Hospital NHS Trust, 1995-1997.
- University of Leeds: School of Medicine Research Dean; School of Medicine Executive Board Member, 1998-2001; Head of Department, 1993-2003; Member of Court, 2003-2005; Member of Senate, 2003-2005.
- Examiner: Royal College of Pathologists; MBBS and BMedSci, University of Oxford; University of London; University College, Dublin ; PhD to most UK Universities.
- Grant Peer Reviewer for all major Medical Research Charities. Association of Medical Research Charities Board, 2003-2007.

Commercial Experience

- 14 years' experience as a Research Scientist/Team Leader/Clinician/Research Manager in GD Searle Pharmaceuticals, then ICI (now AstraZeneca) Pharmaceuticals and Diagnostics. Line and project management responsibilities for multiple groups of 50 plus R&D scientists and clinicians, in pharmaceutical and diagnostics businesses in a number of disease areas, including USA commercial and scientific management experience. Broad experience in patenting/intellectual property matters. Numerous granted patents.
- Executive responsibilities for an ICI (now AstraZeneca) Business Unit. Internal Medical Director role. Experience in identification and evaluation of companies for acquisition or joint-venturing as a member of cross-functional negotiating teams.
- Products developed: Zeneca/Cellmark Diagnostics' DNA Fingerprinting and Genetic Testing business worldwide. Appointed by the Home Secretary under the Family Law Reform Act, 1969, as a Registered Blood Tester for DNA Fingerprinting. Queen's Award for Technological Achievement 1990. Inventor of the "ARMS" technology for diagnostic genetic testing, commercialised by the AZ spin-off company DxS, which was recently sold for ca £100million. Member of the Development Teams for the drugs Raltitrexed (Tomudex), Bicalutamide (Casodex), Anastrozole (Arimidex) and Fulvestrant (Faslodex). As Programme Manager 1989-1991 established the AstraZeneca research group which developed the anticancer drug Gefitinib (Iressa).
- Director and Chief Executive (1995-2002) of a University of Leeds Biotechnology Start-Up Company, Molecular Solutions Limited. Lead business through two rounds of financing.
- Scientific Advisory Board Member, Oxagen plc 1998-2004.
- Bioscience Venture Capital Trust, Board Director 1998-2004 (one of few VCTs to generate a substantial increase in NPV).

- As Chief Executive of Cancer Research UK, completed the merger of the Charity and built an organisation that doubled its annual income over 4 years (ca £230 to £460 million) to create the world's largest fundraising medical research charity. Defined CR-UK's long term Strategy and Goals. Reorganised the Beatson, Gray and Paterson Institutes, built the Cambridge Research Institute and repositioned the London Research Institute. Substantially expanded CR-UK's translational research activities with the NIHR to take 20 new agents into patients each year, through a national network of Experimental Cancer Medicine Centres, with CR-UK Cancer Research Centres for later stage clinical studies. As Chair of the NCRI and through the UKCRC Board, supported the creation of NIHR National Clinical Research Networks, led the lobbying for the 2006 UK-wide Ban on Smoking in Public Places and the National Bowel Cancer Screening Programme, and worked with the National Cancer Director to deliver the 2007 Cancer Reform Strategy.
- Scientific Advisory Board, Roche Pharmaceuticals, 2007-2010.
- Scientific Advisory Board, GSK Clinical Imaging Centre, London, 2010-date.

GENERAL REFEREES

Professor Sir Alan G. Wilson FRS,
Vice-Chancellor (retired),
University of Leeds,
Leeds, LS2 9JT

Professor Sir Alec J. Jeffreys FRS,
Department of Genetics, University of Leicester
Leicester, LE1 7RH

Sir Tom F. W. McKillop,
Chief Executive (retired), AstraZeneca Pharmaceuticals,
Alderley Park, Macclesfield, Cheshire, SK10 4TG

Professor Steven V. Ley FRS,
University Chemical Laboratory, University of Cambridge
Lensfield Road, Cambridge, CB2 1EW

Sir Alan Langlands,
Chief Executive, Higher Education Funding Council for England,
Centre Point, 103 New Oxford Street, London, WC1A 1DD.

Professor Dame Nancy Rothwell FRS,
President and Vice Chancellor, University of Manchester,
A. V. Hill Building, Oxford Road, Manchester, M13 9PT.

CLINICAL REFEREES

Professor Sir David Weatherall FRCP FRS,
Regius Professor of Clinical Medicine (retired),
University of Oxford,
John Radcliffe Hospital, Oxford, OX3 9DU

Professor Dame Sally Davies
Director General, Research and Development,
Interim Chief Medical Officer, Department of Health,
Richmond House, 79 Whitehall, London SW1A 2NS.

Professor Sir John Bell FRS PMedSci,
Regius Professor of Clinical Medicine,
University of Oxford, Richard Doll Building,
Churchill Hospital, Roosevelt Drive, Headington, Oxford, OX3 7DG.

Professor Sir David Carter FRCS, FRSE, FMedSci,
Emeritus Professor of Surgery, University of Edinburgh,
Cancer Research UK,
61 Lincoln's Inn Fields, London WC2A 3PX

Professor Bert Vogelstein,
The Johns Hopkins Oncology Center,
424 North Bond Street,
Baltimore, MD21231, USA

Professor Stuart H. Orkin,
Harvard University Medical School,
The Children's Hospital Medical Centre,
300 Longwood Avenue,
Boston, MA02115, USA

Professor Sir Michael Richards CBE, FRCP, FMedSci,
National Cancer Director, Department of Palliative Medicine,
St Thomas' Hospital, London SE1 7EH.

Peer-Reviewed Research Grant Income

- **Previous Awards available as an Appendix.**
- **Current Awards:**

EPSRC. *Engineering Therapeutic Microbubbles.* £1.3m. 2010-2013.
S Evans (PI), AF Markham, PL Coletta, S Freear, JA Evans, R Bushby, N Thomson and PF Jones.

Cancer Research UK. *Novel Approaches to Cancer Therapeutics.* £500,000. 2008-2016.
AF Markham (PI).

PhD Students (non-clinical)

R.A. Porter	Imperial College London	1981	
W.M. Colledge	N.I.M.R. London (CNAA)		1984
C.R. Newton	Brunel University		1986
A. Bailey	Leeds University	1996	
S. E. Anderson	“ “	1996	
A. Norris	“ “	1997	
J. M. Askham	“ “	1997	
H. C. Ardley	“ “	1997	
D. A. Robinson	“ “	1997	
J. P. Leek	“ “	1998	
I.M. Carr	“ “	1998	
M.A. Calderwood	“ “	1998	
F. Syed	“ “	1998	
K. Pinchin	“ “	1999	
D. Goodwin	“ “	1999	
N. R. Smith	“ “	2000	
A. Middleton	“ “	2000	
E. Barnes	“ “	2000	
M. Houseman	“ “	2001	
S. Gonagle	“ “	2001	
W.K. Lam	“ “	2002	
L. M. Moynihan	“ “	2002	
C. Lynex	“ “	2003	
G. Marston	“ “	(2011)	

PhD Students (Clinical Research Training Fellows)

R. Harun	Leeds University	1997	
A.J. Churchill	“ “	1998	
A.H. Mansur	“ “	1998	
N.S. Brindle	“ “	1999	
A.P. Booth	“ “	1999	
M.A. Aldersley	“ “	1999	
K.A. Southern	“ “	1999	
D.P. McHale	“ “	2000	
R.C.A. Macadam	“ “	2000	
A.P. Jackson	“ “	2000	
B.H. Maraj	“ “	2000	
J.P. Hamlin	“ “	2001	
Y.J. Crow	“ “	2001	
A.R. Craig	“ “	2001	
M. Karayi (MD)	“ “	2001	
R. Achuthan	“ “	2001	
E. S. Ward	“ “	2002	
K.S. Chapple	“ “	2002	
A.W. Morgan	“ “	2002	
P. Moncur	“ “	2002	
M.S. Giles	“ “	2003	
P. Komolmit	“ “	2003	
F.T. Leong	“ “	2003	
B.S. Ubhi	“ “	2004	
G.A. Follows	“ “	2004	
T. Lee	“ “	2005	
S Uppal	“ “	2010	
N Touqan	“ “	(2013)	

PUBLICATIONS

1. A Simple Method for the Preparation of “Ribonucleoside Dialdehydes” and Comments on their Structure.
A. S. Jones, A. F. Markham and R. T. Walker.
J. Chem. Soc. Perkin 1, 1567-1570 (1976).
2. The Synthesis of Poly (Acrylic Acid Hydrazide) with Poly (Methacrylic Acid Hydrazide) and their Reaction Products with “Ribonucleoside Dialdehydes”.
A.S. Jones, A. F. Markham and R. T. Walker.
Tetrahedron, 32, 2361-2364 (1976).
3. Synthesis of *E. coli* tRNA^{fmet} Fragments.
E. Ohtsuka, A. F. Markham, S. Tanaka, T. Tanaka, T. Miyake, E. Nakagawa, S. Nishikawa and M. Ikehara.
Nucleic Acids Research, 2, 77-81 (1976).
4. Recent Progress in the Synthesis of Ribooligonucleotides Related to tRNA.
E. Ohtsuka, A. F. Markham, S. Nishikawa, S. Tanaka, T. Tanaka, T. Miyake, E. Nakagawa and M. Ikehara.
in “Synthesis, Structure and Chemistry of Transfer Ribonucleic Acids”,
M. Wiewiorowski ed, Polish Academy of Sciences, Poznan, pp 173-185 (1976).
5. An Approach to the Synthesis of Intermediate Sized Oligoribonucleotides.
A. F. Markham, T. Miyake, E. Ohtsuka and M. Ikehara.
Heterocycles, 8, 229-233 (1977).
6. Joining of Synthetic Ribotrinucleotides with Defined Sequences Catalysed by T4 RNA Ligase.
E. Ohtsuka, S. Nishikawa, R. Fukumoto, S. Tanaka, A. F. Markham, M. Ikehara and M. Sugiura.
Eur. J. Biochem., 81, 285-291 (1977).
7. Synthesis of Escherichia coli tRNA^{fmet} fragments (1-20, 47-77).
E. Ohtsuka, T. Tanaka, S. Tanaka, A. F. Markham, T. Miyake, E. Nakagawa, S. Nishikawa and M. Ikehara.
Nucleic Acids Research, 3, 117-121 (1977).
8. Studies on tRNA and Related Compounds XXI. Synthesis and Properties of Guanine Rich Fragments from *E. coli* tRNA^{fmet} 5'-end.
E. Ohtsuka, E. Nakagawa, T. Tanaka, A. F. Markham and M. Ikehara.
Chem. Pharm. Bull., 26, 2998-3006 (1978).
9. Joining of 3'-Modified Oligonucleotides by T4 RNA Ligase. Synthesis of a Heptadecanucleotide Corresponding to the bases 61-77 from *E. coli* tRNA^{fmet}.
E. Ohtsuka, S. Nishikawa, A. F. Markham, S. Tanaka, T. Miyake, T. Wakabayashi, M. Ikehara and M. Sugiura.
Biochemistry, 17, 4894-4899 (1978).

10. The Synthesis of Polynucleotides.
M. Ikehara, E. Ohtsuka and A. F. Markham.
in “Advances in Carbohydrate Chemistry and Biochemistry”, R S Tipton and D Horton eds,
Academic Press, New York, Vol 36, pp 135-213 (1979).
11. Influence of Terminal 3'-Phosphates or 2', 3'-Cyclic Phosphates on the Conformations of
Oligoriboadenylates, Oligoribocytidylates and the Corresponding Monomers.
A. F. Markham, S. Uesugi, E. Ohtsuka and M. Ikehara.
Biochemistry, 18, 4936-4942 (1979).
12. Studies on tRNA and Related Compounds XXVII. Linear and Cyclic Oligonucleotides
Obtained by Polymerisation of Protected Ribonucleoside 3'-Phosphates.
A. F. Markham, E. Nakagawa, E. Ohtsuka and M. Ikehara.
Chem. Pharm. Bull., 27, 2988-2996 (1979).
13. Rapid Chemical Synthesis and Circular Dichroism Properties of Some 2'-5'-linked
Oligoriboadenylates.
A. F. Markham, R. A. Porter, M. J. Gait, R. C. Sheppard and I. M. Kerr.
Nucleic Acids Research, 6, 2569-2582 (1979).
14. Synthesis of the Nascent Strand of tRNA^{met} from *E. coli*.
E. Ohtsuka, T. Tanaka, S. Tanaka, K. Fujiyama, A. F. Markham, E. Nakagawa,
T. Wakabayashi, Y. Taniyama, S. Nishikawa, R. Fukumoto, H. Uemura, T. Doi and
M. Ikehara.
Nucleic Acids Research, 6, 195-198 (1979).
15. Synthesis of Total Fragments of tRNA^{met} from *E. coli*.
E. Ohtsuka, S. Tanaka, S. Nishikawa, T. Miyake, T. Tanaka, E. Nakagawa, T. Wakabayashi,
A. F. Markham, J. Antkowiak and M. Ikehara.
in “Nucleosides, Nucleotides and their Biological Applications”,
J-L Barascut and J-L Imbach eds, Colloq de l'INSERM, 81, 195-206 (1979).
16. Studies on tRNA and Related Compounds XXVI. Circular Dichroism Properties of Cyclic
Oligoribonucleotides and their Linear Counterparts.
A. F. Markham, E. Nakagawa, E. Ohtsuka and M. Ikehara.
Biopolymers, 19, 285-296 (1980).
17. Studies on tRNA and Related Compounds XXXIV. Stepwise Diester or Partial Triester
Synthesis of Penta- to Octanucleotides Corresponding to Residues 41-46, 47-54, 61-65 and 66-
71 of tRNA^{met} of *E. coli*.
E. Ohtsuka, T. Miyake, A. F. Markham, E. Nakagawa and M. Ikehara.
Chem. Pharm. Bull., 28, 2450-2459 (1980).
18. Synthesis of tRNA^{met} from *E. coli*.
M. Ikehara, E. Ohtsuka, S. Tanaka, S. Nishikawa, T. Tanaka, T. Miyake, E. Nakagawa,
T. Wakabayashi, R. Fukumoto, H. Uemura, Y. Taniyama, T. Doi, A. F. Markham and
J. Antkowiak.
in “Phosphorus Chemistry Directed Towards Biology”,
W. J. Stec ed, Pergamon Press, New York, pp 33-45 (1980).

19. Rapid Synthesis of Oligodeoxyribonucleotides IV. Improved Solid Phase Synthesis of Oligodeoxyribonucleotides through Phosphotriester Intermediates.
M. J. Gait, M. Singh, R. C. Sheppard, M. D. Edge, A. R. Greene, G. R. Heathcliffe, T. C. Atkinson, C. R. Newton and A. F. Markham.
Nucleic Acids Research, 8, 1081-1096 (1980).
20. Total Synthesis of tRNA^{phe}.
E. Ohtsuka, A. F. Markham, S. Tanaka, T. Tanaka, T. Miyake, E. Nakagawa, T. Wakabayashi, Y. Taniyama, K. Fujiyama, S. Nishikawa, R. Fukumoto, H. Uemura, T. Doi, T. Tokunaga and M. Ikehara.
Nucleic Acids Research, 7, 335-343 (1980).
21. Solid Phase Phosphotriester Synthesis of Large Oligodeoxyribonucleotides on a Polyamide Support.
A. F. Markham, M. D. Edge, T. C. Atkinson, A. R. Greene, G. R. Heathcliffe, C. R. Newton and D. B. Scanlon.
Nucleic Acids Research, 8, 5193-5205 (1980).
22. Total Synthesis of a Human Leukocyte Interferon Gene.
M. D. Edge, A. R. Greene, G. R. Heathcliffe, P. A. Meacock, W. Schuch, D. B. Scanlon, T. C. Atkinson, C. R. Newton and A. F. Markham.
Nature, 292, 756-762 (1981).
23. Total Synthesis of a RNA Molecule with sequence identical to that of *Escherichia coli* formylmethionine tRNA..
E. Ohtsuka, S. Tanaka, T. Tanaka, T. Miyake, A. F. Markham, E. Nakagawa, T. Wakabayashi, Y. Taniyama, S. Nishikawa, R. Fukumoto, H. Uemura, T. Doi, T. Tokunaga and M. Ikehara.
Proc. Natl. Acad. Sci. USA, 78, 5493-5497 (1981).
24. Applications of Oligonucleotide Synthesis to Interferon Research.
M. D. Edge and A. F. Markham.
Biochim. Biophys. Acta Reviews on Cancer, 695, 35-48 (1982).
25. Isolation of cDNA clones for the Human complement protein Factor B, a class III major histocompatibility complex gene product.
D. E. Woods, A. F. Markham, A. T. Ricker, G. Goldberger and H. R. Colten.
Proc. Natl. Acad. Sci. USA, 79, 5661-5665 (1982).
26. Synthesis of some 5'-Amino-2' , 5'-Dideoxy-5-Iodouridine Derivatives and their Antiviral Properties against Herpes Simplex Virus.
A.F. Markham, C.R. Newton, R.A. Porter and I.S.Sim.
Antiviral Research, 2, 319-330 (1982).
27. The construction of a synthetic *Escherichia coli* Trp promoter and its use in the expression of a synthetic interferon gene.
J.D. Windass, C.R. Newton, J. de Maeyer-Guignard, V.E. Moore, A.F. Markham and M.D. Edge.
Nucleic Acids Research, 10, 6639-6657 (1982).

28. Ion-exchange High Performance Liquid Chromatography of Oligodeoxyribonucleotides using Formamide.
C.R. Newton, A.R. Greene, G.R. Heathcliffe, T.C. Atkinson, D. Holland, A.F. Markham and M.D. Edge.
Analytical Biochemistry, 129, 22-30 (1983).
29. Isolation and DNA sequence of a full length cDNA clone for human X-chromosome encoded phosphoglycerate kinase.
A.M. Michelson, A.F. Markham and S.H. Orkin.
Proc. Natl. Acad. Sci. USA, 80, 472-476 (1983).
30. Anti-Oxazolone Hybridomas and the Structure of the Oxazolone Idiotypic.
M. Kaartinen, G.M. Griffiths, P.H. Hamlyn, A.F. Markham, K. Karjalainen, J.L.T. Pelkonen, O. Makela and C. Milstein.
J. Immunology, 130, 937-945 (1983).
31. Direct detection of the common Mediterranean β -Thalassemia gene with synthetic DNA Probes; an alternative approach for prenatal diagnosis.
S.H. Orkin, A.F. Markham and H.H. Kazazian.
J. Clin. Investigation., 71, 775-779 (1983).
32. Dynamics of cruciform extrusion in supercoiled DNA : Use of a synthetic inverted repeat to study conformational populations.
D.M.J. Lilley and A.F. Markham.
EMBO Journal, 2, 527-533 (1983).
33. The molecular basis of transformation by polyoma virus middle-T.
A.E. Smith, S.A. Courtneidge, B.A. Oostra, B.K. Ely, R. Harvey and A.F. Markham.
Cell. Biol. Int. Reports, 7, 507-508 (1983).
34. Isolation of Human C-Reactive Protein cDNA and localisation of the Gene to Chromosome 1.
A.S. Whitehead, G.A.P. Bruns, A.F. Markham, H.R. Colten and D.E Woods.
Science, 221, 69-71 (1983).
35. Isolation of a cDNA clone for Human Antithrombin III.
E.V. Prochownik, A.F. Markham and S.H. Orkin.
J. Biol. Chem., 258, 8389-8394 (1983).
36. mRNA sequences define an unusually restricted IgG response to 2-phenyl oxazolone and its early diversification.
M. Kaartinen, G.M. Griffiths, A.F. Markham and C. Milstein.
Nature, 304, 320-324 (1983).
37. Transforming activity of polyoma virus middle-T antigen probed by site-directed mutagenesis.
B.A. Ostra, R. Harvey, B.K. Ely, A.F. Markham and A.E. Smith.
Nature, 304, 456-459 (1983).

38. Chemical synthesis of a human interferon α -2 gene and its expression in *Escherichia coli*.
M.D. Edge, A.R. Greene, G.R. Heathcliffe, V.E. Moore, N.J. Faulkner, R. Camble,
N.N. Petter, P. Trueman, W. Schuch, J. Hennam, T.C. Atkinson, C.R. Newton and
A.F. Markham.
Nucleic Acids Research, 11, 6419-6435 (1983).
39. Use of a cDNA clone for the fourth component of human complement (C4) for analysis of a
genetic deficiency of C4 in guinea pig.
A.S. Whitehead, G. Goldberger, D.E. Woods, A.F. Markham and H.R. Colten.
Proc. Natl. Acad. Sci. USA, 80, 5387-5391 (1983).
40. Molecular Cloning of Human Adenosine Deaminase Gene Sequences.
S.H. Orkin, P.E. Daddona, D.S. Shewach, A.F. Markham, G.A. Bruns, S.C. Goff and
W.N. Kelley.
J. Biol. Chem., 258, 12753-12756 (1983).
41. The Isolation of cDNA clones for Human Apolipoprotein E and the detection of apoE in hepatic
and extra-hepatic tissues.
S. Wallis, S. Rogne, L. Gill, A.F. Markham, M.D.Edge, D.E. Woods, R. Williamson and
S.E. Humphries.
EMBO Journal, 2, 2369-2372 (1983).
42. Recurrent Mutation, Gene Migration and possibly Interallelic Gene Conversion contribute to
mutation spread in human populations.
H.H. Kazazian, S.H. Orkin, S.E. Antonarakis, H. Youssoufian, A.F. Markham, C.D. Boehm and
P.G. Waber.
Amer. J. Hum. Genet., 35, 175 (1983).
43. The Isolation and Characterisation of cDNA clones for Human Apolipoprotein C-II.
O. Mykelbost, R. Williamson, A.F. Markham, S.R. Mykelbost, J. Rogers, D.E. Woods and
S.E. Humphries.
J. Biol. Chem., 259, 4401-4404 (1984).
44. β -Thalassemia in the Chinese: Use of in vivo RNA analysis and oligonucleotide hybridisation in
systematic characterisation of molecular defects.
T. Cheng, S.H. Orkin, S.E. Antonarakis, M.J. Potter, J.P. Sexton, A.F. Markham,
P.J.V. Giardina, A. Li and H.H. Kazazian.
Proc. Natl. Acad. Sci. USA, 81, 2821-2825 (1984).
45. Quantification of the close association between DNA haplotypes and specific β -thalassemia
mutations in Mediterraneans.
H.H. Kazazian, S.H. Orkin, A.F. Markham, C.R. Chapman, H.A. Youssoufian and
P.G. Waber.
Nature, 310, 152-154 (1984).
46. Sequence requirements for nuclear location of SV40 large-T antigen.
D. Kalderon, W.D. Richardson, A.F. Markham and A.E. Smith.
Nature, 311, 33-38 (1984).

47. Human Adenosine Deaminase: cDNA and complete primary amino acid sequence.
P.E. Daddona, D.S. Shewach, W.N. Kelley, P. Argos, A.F. Markham and S.H. Orkin.
J. Biol. Chem., 259, 12101-12106 (1984).
48. Isolation of cDNA clones encoding the 20K T3 glycoprotein of human T-cell receptor complex.
P. van den Elsen, B. Shepley, J. Borst, J.E. Coligan, A.F. Markham, S.H. Orkin and C. Terhorst.
Nature, 312, 413-418 (1984).
49. The use of synthetic oligonucleotides in the detection of the z variant of alpha-1-antitrypsin.
N. Kalsheker, G.L. Watkins, A.F. Markham, D. Chiswell, S.E. Humphries and R. Williamson.
Biochem. Soc. Trans., 12, 671-672 (1984).
50. Possible applications of recombinant DNA technology to the diagnosis and study of variants of alpha-1-antitrypsin.
N. Kalsheker, D. Chiswell, A.F. Markham, A. Imam, S. Wallis, R. Williamson and S.E. Humphries.
Annals of Clinical Biochemistry, 22, 25-32 (1985).
51. Isolation and characterisation of a cDNA clone for Human Apolipoprotein C-I and assignment of the gene to chromosome 19.
F. Tata, I. Henry, A.F. Markham, S.C. Wallis, D. Weil, K.H. Grzeschik, C. Junien, R. Williamson and S.E. Humphries.
Human Genetics, 69, 345-349 (1985).
52. The Nuclear Location Signal.
A.E. Smith, D.E. Kalderon, B.L. Roberts, W.H. Colledge, M.D. Edge, P. Gillett, A.F. Markham, E. Paucha and W.D. Richardson.
Proc. R. Soc. London B, 226, 43-58 (1985).
53. Gene K of Bacteriophage ϕ X174 codes for a protein which affects the burst size of phage production.
S. Gillam, T.C. Atkinson, A.F. Markham and M. Smith.
J. Virology, 53, 708-709 (1985).
54. Identification of a point mutation in the Adenosine Deaminase Gene responsible for Immunodeficiency.
D.T. Bonthron, A.F. Markham, D. Ginsburg and S.H. Orkin.
J. Clin. Invest., 76, 894-897 (1985).
55. Site-Directed Mutagenesis of Polyomavirus Middle-T Antigen Sequences encoding Tyrosine 315 and Tyrosine 250.
W. Markland, B.A. Oostra, R. Harvey, A.F. Markham, W.H. Colledge and A.E. Smith.
J. Virology, 59, 384-391 (1986).
56. Mutations around the NG59 lesion indicate an active association of polyoma virus middle-T antigen with pp60^{c-src} is required for cell transformation.
S.H. Cheng, W. Markland, A.F. Markham and A.E. Smith.
EMBO Journal, 5, 325-334 (1986).

57. Two Regions Downstream of AATAAA in the Human Antithrombin III Gene are important for Cleavage-Polyadenylation.
E.V. Prochownik, M.J. Smith and A.F. Markham.
J. Biol. Chem., 262, 9004-9010 (1987).
58. The isolation and characterisation of cDNA and genomic clones for human lecithin : cholesterol acyltransferase.
F. Tata, M.E. Chaves, A.F. Markham, G.D. Scrace, M.D. Waterfield, N. McIntyre, R. Williamson and S.E. Humphries.
Biochim. Biophys. Acta, 910, 142-148 (1987).
59. Normal Keratinization in a Spontaneously Immortalised Aneuploid Human Keratinocyte Cell Line.
P. Boukamp, R.T. Petrussevska, D. Breitkreutz, J. Hornung, A.F. Markham and N.E. Fusenig.
J. Cell Biol., 106, 761-771 (1988).
60. Diagnosis of α -1-antitrypsin deficiency by enzymatic amplification of human genomic DNA and direct sequencing of polymerase chain reaction products.
C.R. Newton, N. Kalsheker, A. Graham, S.J. Powell, A. Gammack, J.H. Riley and A.F. Markham.
Nucleic Acids Research, 16, 8233-8243 (1988).
61. Use of the Polymerase Chain Reaction and direct sequencing for prenatal diagnosis of α -1-antitrypsin deficiency.
C.R. Newton, N. Kalsheker, A. Graham, J.H. Riley, S.J. Powell, A. Gammack and A.F. Markham.
Biochem. Soc. Trans., 17, 367-368 (1989).
62. Analysis of any point mutation in DNA. The Amplification Refractory Mutation System (ARMS).
C.R. Newton, A. Graham, L.E. Heptinstall, S.J. Powell, C. Summers, N. Kalsheker, J.C. Smith and A.F. Markham.
Nucleic Acids Research, 17, 2503-2516 (1989).
63. Specificity of the Polymerase Chain Reaction in the Study of α -1-Antitrypsin Deficiency.
A. Graham, C.R. Newton, S.J. Powell, L.E. Heptinstall, C. Summers, L. Brown, R. Anwar, K. Murray, A. Gammack, R. Kennedy, N. Kalsheker and A.F. Markham.
in "Polymerase Chain Reaction", eds H.A. Erlich, R. Gibbs and H.H. Kazazian,
Current Communications in Mol. Biol., Cold Spring Harbor Laboratory Press, New York, pp 105-110 (1989).
64. Molecular characterisation of three α -1-antitrypsin deficiency variants:
Proteinase inhibitor (Pi) null_{cardiff} (Asp²⁵⁶ -> Val); Pi M_{malton} (Phe⁵¹ -> deletion)
and Pi I (Arg³⁹ -> Cys).
A. Graham, N.A. Kalsheker, C.R. Newton, F.J. Bamforth, S.J. Powell and A.F. Markham.
Human Genetics, 84, 55-58 (1989).
65. The development of methods for the analysis of DNA extracted from Forensic Samples.
B. Hopkins, J.E.N. Morten, J.C. Smith and A.F. Markham.
Technique, 1, 96-102 (1989).

66. Rapid determination of DNA concentration in multiple samples.
J.H. Riley, D.E. Jenner, J.C. Smith and A.F. Markham.
Nucleic Acids Research, 17, 8383-8384 (1989).
67. Nucleotide sequence of cDNA for Human Aldose Reductase.
A. Graham, P.J. Hedge, S.J. Powell, J.H. Riley, L. Brown, A. Gammack, F. Carey and A.F. Markham.
Nucleic Acids Research, 17, 8368-8369 (1989).
68. Amplification Refractory Mutation System for prenatal diagnosis and carrier assessment in Cystic Fibrosis.
C.R. Newton, L.E. Heptinstall, C. Summers, M. Super, M. Schwarz, R. Anwar, A. Graham, J.C. Smith and A.F. Markham.
Lancet, ii, 1481-1483 (1989).
69. Highly polymorphic minisatellite DNA probes. Further evaluation for individual identification and paternity testing.
J.C. Smith, C.R. Newton, A. Alves, R. Anwar, D.E. Jenner and A.F. Markham.
J. Forensic Science Soc., 30, 3-18 (1990).
70. Highly polymorphic minisatellite sequences: allele frequencies and mutation rates for five locus-specific probes in a Caucasian population.
J.C. Smith, R. Anwar, J. Riley, D.E. Jenner, A.F. Markham and A.J. Jeffreys.
J. Forensic Science Soc., 30, 19-32 (1990).
71. DNA sequence analysis of the KM19 locus linked to Cystic Fibrosis. Design of new oligonucleotides to remove non-specific PCR products.
R. Anwar, K. Murray, P.J. Hedge, J.C. Smith and A.F. Markham.
Human Genetics, 85, 319-323 (1990).
72. Human cDNA sequence homologous to the mouse LLRep 3 gene family.
G. Slyn, D.E. Jenner, W. Potts, P. Elvin, J.E.N. Morten and A.F. Markham.
Nucleic Acids Research, 18, 681 – 682 (1990).
73. Characterisation of the α -1-antitrypsin M3 gene, a normal variant.
A. Graham, K. Hayes, S. Weidinger, C.R. Newton, A.F. Markham and N. Kalsheker.
Human Genetics, 85, 381-382 (1990).
74. Localisation of a cDNA clone for Human Cytokeratin 18 to chromosome 17p11-p12 by *in situ* hybridisation.
P. Heath, P. Elvin, D.E. Jenner, A. Gammack, J.E.N. Morten and A.F. Markham.
Human Genetics, 85, 669-670 (1990).
75. A 3.6 Genome Equivalent Multi Access YAC Library: Construction, Characterisation, Screening and Storage.
R. Anand, J.H. Riley, R. Butler, J.C. Smith and A.F. Markham.
Nucleic Acids Research, 18, 1951-1956 (1990).

76. A novel, rapid method for the isolation of terminal sequence from yeast artificial chromosome (YAC) clones.
J.H. Riley, R. Butler, D. Ogilvie, R. Finnear, D.E. Jenner, S. Powell, R. Anand, J.C. Smith and A.F. Markham.
Nucleic Acids Research, 18, 2887-2890 (1990).
77. Detection of F₅₀₈ deletion in cystic fibrosis by amplification refractory mutation system.
C.R. Newton, M. Schwarz, C. Summers, L.E. Heptinstall, A. Graham, J.C. Smith, M. Super and A.F. Markham.
Lancet, i, 1217-1219 (1990).
78. Isolation of cDNA clones using Yeast Artificial Chromosome Probes.
P. Elvin, G. Slyn, D. Black, A. Graham, R. Butler, J. Riley, R. Anand and A.F. Markham.
Nucleic Acids Research, 18, 3913-3917 (1990).
79. Molecular Characterization of two alpha-1-antitrypsin deficiency variants: Proteinase inhibitor (Pi) Null_{Newport} (Gly¹¹⁵ -> Ser) and (Pi) Z_{Wrexham} (Ser¹⁹ -> Leu).
A. Graham, N.A. Kalsheker, F.J. Bamforth, C.R. Newton and A.F. Markham.
Human Genetics, 85, 537-540 (1990).
80. Del F508 CF testing of the DNA bank of the Royal Manchester Children's Hospital.
M.J. Schwarz, M. Super, C. Wallis, P. Beighton, C.R. Newton, L.E. Heptinstall, C. Summers, A.F. Markham, G. Hambleton, K.W. Webb, D. Bilton, D. Heaf and M. Dalzell.
Human Genetics, 85, 428-430 (1990).
81. Human Aldose Reductase Gene Maps to Chromosome Region 7q35.
A. Graham, P. Heath, J.E.N. Morten and A.F. Markham.
Human Genetics, 86, 509-514 (1991).
82. Genetic analysis in cystic fibrosis using the Amplification Refractory Mutation System (ARMS): the J3.11 locus.
C.R. Newton, C. Summers, L.E. Heptinstall, J.R. Lynch, R.S. Finnear, D. Ogilvie, J.C. Smith and A.F. Markham.
J. Med. Genet., 28, 248-251 (1991).
83. A Yeast Artificial Chromosome Contig Encompassing the Cystic Fibrosis Locus.
R. Anand, D.J. Ogilvie, R. Butler, J.H. Riley, R.S. Finnear, S.J. Powell, J.C. Smith and A.F. Markham.
Genomics, 9, 124-130 (1991).
84. Structure of the Human Aldose Reductase Gene.
A. Graham, L. Brown, P.J. Hedge, A.J. Gammack and A.F. Markham.
J. Biol. Chem., 266, 6872-6877 (1991).
85. 2 Sequence Tagged Sites defining a 380kB YAC clone (8IC8) adjacent to the Myotonic Dystrophy locus.
R. Butler, J.H. Riley, D.J. Ogilvie, J. Buxton, J. Davies, K. Johnson, R. Anand and A.F. Markham.
Nucleic Acids Research, 19, 4787-89 (1991).

86. A plasmid cassette system that allows optimisation of primers for use in the Amplification Refractory Mutation System.
C.R. Newton, C. Summers, L.E. Heptinstall, D.E. Jenner, A. Graham and A.F. Markham.
Biotechniques, 10, 582-588 (1991).
87. Identification of a Chromosome 5q21 Gene that is Mutated in Colorectal Cancers.
K.W. Kinzler, M.C. Nilbert, B. Vogelstein, T.M. Bryan, D.B. Levy, K.J. Smith, A.C. Preisinger, S.R. Hamilton, P.J. Hedge, A.F. Markham, M. Carlson, G. Joslyn, J. Groden, R.L. White, Y. Miki, Y. Miyoshi, I. Nishisho and Y. Nakamura.
Science, 251, 1366-1370 (1991).
88. Some Applications of Molecular Biology in Medicine.
A.F. Markham.
in "Horizons in Medicine", eds. C.A. Seymour and J. Summerfield,
Royal College of Physicians, Bailliere Tindall, London, Vol. 3, pp 178-191, (1991).
89. Direct haplotype determination by double ARMS: genetic applications.
Y-M. D. Lo, P. Patel, C.R. Newton, A.F. Markham, K.A. Fleming and J.S. Wainscoat.
Nucleic Acids Research, 19, 3561-3567 (1991).
90. A deletion mutation of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) locus : Delta I₅₀₇.
M. Schwarz, M. Super, C. Summers, L. Heptinstall, C.R. Newton and A.F. Markham.
Advances in Experimental Medicine and Biology, 290, 393-398 (1991).
91. Isolation of the FAP locus on Chromosome 5q21.
K.W. Kinzler, M.C. Nilbert, L-K. Su, B. Vogelstein, T.M. Bryan, D.B. Levy, K.J. Smith, A.C. Preisinger, P.J. Hedge, D. McKechnie, R. Finnear, A.F. Markham, J. Groffen, M.S. Boguski, S.F. Altschul, A. Horii, H. Ando, Y. Miyoshi, Y. Miki, I. Nishisho and Y. Nakamura.
Science, 253, 661-665 (1991).
92. Somatic and Germline Mutations of Chromosome 5q21 Genes in Colorectal Cancer Patients.
I. Nishisho, Y. Nakamura, Y. Miyoshi, Y. Miki, H. Ando, A. Horii, K. Koyama, J. Utsunomiya, S. Baba, P.J. Hedge, A.F. Markham, G. Petersen, S.R. Hamilton, M.C. Nilbert, D.B. Levy, T.M. Bryan, A.C. Preisinger, K.J. Smith, L-K. Su, K.W. Kinzler and B. Vogelstein.
Science, 253, 665-669 (1991).
93. Direct haplotype determination by double Amplification Refractory Mutation System (double ARMS) : a model system using a highly polymorphic region 5' to the human delta-globin gene on Chromosome 11.
Y-M. D. Lo, P. Patel, C.R. Newton, A.F. Markham, K.A. Fleming and J.S. Wainscoat.
Cytogenet. Cell Genet., 58, 1966-1967 (1991).
94. The Vectorette : a Tool for Genomic Walking.
D.J. Ogilvie, R. Butler, J.H. Riley and A.F. Markham.
Cytogenet. Cell Genet., 58, 2151-2152 (1991).

95. Vectorette PCR : a novel approach to genomic walking.
I.J. Hodgson, C. Arnold, A. Alves, D.J. Ogilvie, R. Butler, J.C. Smith, R. Anwar and A.F. Markham.
Miami Winter Symposium Short Reports, 1, 49-50 (1991).
96. A 1.6Mb YAC contig at the FAP locus (5q21-q22) contains the gene for MCC and other candidate genes.
P.J. Hedge, D. McKechnie, A. Gammack, R. Finnear, J. Ellston, K. Kinzler, B. Vogelstein, Y. Nakamura and A.F. Markham.
Amer. J. Hum. Genet., 49, 101 (1991).
97. YAC clones comprising 5.5Mb of DNA at the FAP locus (5q21) in six contigs allow localisation of polymorphic markers and candidate tumour suppressor genes.
P.J. Hedge, D. McKechnie, A. Gammack, J.H. Riley, J. Ellston, K. Kinzler, B. Vogelstein, Y. Nakamura and A.F. Markham.
J. Cell. Biochem., 15H, 31 (1991).
98. YAC cloning of Human Chromosome 17q21, the location of a gene for Familial Breast Cancer.
K. Hudson, D.J. Ogilvie and A.F. Markham.
Amer. J. Hum. Genet., 49, 2306 (1991).
99. Walking, Cloning and Mapping with Yeast Artificial Chromosomes. A Contig Encompassing D21S13 and D21S16.
R. Butler, D.J. Ogilvie, P. Elvin, J.H. Riley, R.S. Finnear, G. Slynn, J.E.N. Morten, R. Anand and A.F. Markham.
Genomics, 12, 42-51 (1992).
100. Application of PCR to Human Gene Detection.
Y-M. D. Lo and A.F. Markham.
Current Opinion in Biotechnology, 3, 8-11 (1992).
101. Characterization of a YAC and Cosmid Contig containing markers tightly linked to the Myotonic Dystrophy Locus on Chromosome 19.
J. Buxton, P. Shelbourne, J. Davies, C. Jones, M.B. Perryman, T. Ashizawa, R. Butler, D. Brook, D. Shaw, P. de Jong, A.F. Markham, R. Williamson and K. Johnson.
Genomics, 13, 526-531 (1992).
102. A Human Aldehyde Dehydrogenase (Aldose Reductase) Pseudogene: nucleotide sequence analysis and assignment to Chromosome 3.
L. Brown, P.J. Hedge, A. Graham and A.F. Markham.
Genomics, 13, 465-468 (1992).
103. Human aldose reductase : characterisation of the functional gene and a search for a link between a polymorphic site and complications in patients with diabetes.
A. Graham, L. Brown, J.H.B. Scarpello, L. Alexander and A.F. Markham.
Diabetic Medicine, 9, S23 (1992).
104. Isolation of YACs for CSF-1R and CSF-1 and gene localisation using FISH.
J. Boultonwood, K. Rack, P.J. Hedge, A.F. Markham, J.S. Wainscoat and V.J. Buckle.
Cytogenet. Cell. Genet., 61, 232 (1992).

105. The production of PCR products with 5' single-stranded tails using primers that incorporate novel phosphoramidite intermediates.
C.R. Newton, D. Holland, L.E. Heptinstall, I. Hodgson, M.D. Edge, M.J. McLean and A.F. Markham.
Nucleic Acids Research, 21, 1155-1162 (1993).
106. PCR, a Tool for Molecular Medicine.
A.F. Markham.
in "Basic Molecular and Cell Biology",
British Medical Journal Books, London, 2nd edition, pp 34-39, (1993)
and
British Medical Journal, 306, 441-446 (1993).
107. Screening for Cancer Predisposition.
A.F. Markham, P.L. Coletta, P.A. Robinson, P.M. Clissold, G.R. Taylor, I.M. Carr and D.M. Meredith.
European J. Cancer, 30A, 2015-2029 (1994).
108. Comparative Genetic Mapping Toward Identification of Novel Diagnostic and Therapeutic Targets.
P.L. Coletta, N.J. Lench, K.A. Brown and A.F. Markham.
Current Opinion in Biotechnology, 5, 643-647 (1994).
109. Autozygosity Mapping of Autosomal Recessive Non-syndromic Sensorineural Hearing Loss (ARNSSNHL).
K.A. Brown, G. Karbani, A. Nobel, A.H. Janjua, V. Newton, R. F. Mueller and A.F. Markham.
Amer. J. Hum. Genet., 55, A181, 1051 (1994).
110. Molecular Genetics of Colon Cancer.
A.F. Markham, P.M. Clissold, A. Bailey, P.L. Coletta, A. Norris, P.J. Guillou, J. Leek and D.M. Meredith.
In "Horizons in Medicine", ed. S Holgate.
Royal College of Physicians, Balliere-Tindall, London, Vol 6, pp104-118 (1995).
111. Some PCR-based approaches to Human Genome Mapping.
J.F.J. Morrison and A.F. Markham.
In "PCR: A Practical Approach", eds. M.J. McPherson, B.D. Hames and G.R. Taylor.
IRL/Oxford University Press, Second Edition, pp165-196 (1995).
112. Yeast Artificial Chromosome Cloning of the β -Catenin Locus on Human Chromosome 3p21-22.
A. Bailey, A.L. Norris, J.P. Leek, P.M. Clissold, I.M. Carr, D.J. Ogilvie, J.F.J. Morrison, D.M. Meredith and A.F. Markham.
Chromosome Research, 3, 201-203 (1995).
113. Molecular basis of inherited factor XIII deficiency: identification of multiple mutations provides insights into protein function.
R. Anwar, A.D. Stewart, K.J.A. Milosewski, M.S. Losowsky and A.F. Markham.
British J. Haematology, 91, 728-735 (1995).
114. A human ubiquitin conjugating enzyme, L-UBC, maps in the Alzheimer's disease locus on Chromosome 14q24.3.

- P.A. Robinson, J. Leek, J. Thompson, I.M. Carr, A. Bailey, T. Moynihan, P.L. Coletta, N. Lench and A.F. Markham.
Mammalian Genome, 6, 725-731 (1995).
115. Prostate-specific Membrane Antigen: Evidence for the Existence of A Second Related Human Gene.
J. Leek, N. Lench, B. Maraj, A. Bailey, I.M. Carr, S. Andersen, J. Cross, P. Whelan, K.A. MacLennan, D.M. Meredith and A.F. Markham.
British J. Cancer, 72, 583-588 (1995).
 116. (CGG) Trinucleotide Repeat Polymorphism in the 5'-region of the HHR6B gene, the human homolog of the yeast DNA repair gene RAD6.
N. J. Lench, J. Thompson, P.A. Robinson and A.F. Markham.
Human Genetics, 96, 369-370 (1995).
 117. Molecular Genetic Analysis of the Human Sorbitol Dehydrogenase Gene.
I.M. Carr and A.F. Markham.
Mammalian Genome, 6, 645-652 (1995).
 118. Human Glucokinase Regulatory Protein (GCKR): cDNA and Genomic Cloning, Complete Primary Structure and Chromosomal Localization.
J.P. Warner, J.P. Leek, S. Intody, A.F. Markham and D.T. Bonthron.
Mammalian Genome, 6, 532-536 (1995).
 119. Identification of Mutations Causing Factor XIIIa Subunit Deficiency in Five Unrelated Families.
R. Anwar, A.D. Stewart, K.J.A. Milosewski, M.S. Losowsky and A.F. Markham.
Blood Coagulation and Fibrinolysis, 6, 342-343 (1995).
 120. Chromosomal Localisation of Terminal Differentiation Genes Differentially Expressed Between Keratocyst and Normal Oral Epithelia.
P.A. Robinson, H. Kazemi, J.P. Leek, W.J. Hume and A.F. Markham.
J. Dent. Res., 74, 824-825 (1995).
 121. Identification and Isolation of Expressed DNA Sequences from the Region Containing the NBCCS Locus.
N.J. Lench, P.A. Robinson and A.F. Markham.
Ann. Hum. Genet., 59, 376-378 (1995).
 122. Transgenic Models and Cancer Treatment.
P.L. Coletta, E.J. Cartwright and A.F. Markham.
Cancer Treatment Reviews, 21, 565-576 (1995).
 123. Identification of Differentially Expressed Genes in CD19 Positive B lymphocytes in Allergic Asthma.
R.B. Harun, A.F. Markham and J.F.J. Morrison.
In: "New Horizons in Allergy Immunotherapy", eds A Sehon and D Kraft, Plenum Press, New York, Chapter 53, pp 375-380 (1996).
Advances in Exp. Med. and Biol., 409, 375-380 (1996).
 124. Non-random Usage of T Cell Receptor α Gene Repertoire in Atopy Using Anchored PCR.
A.H. Mansur, C.M. Gelder, D. Holland, D.A. Campbell, A. Griffin, A.F. Markham and J.F.J. Morrison.

- In: "New Horizons in Allergy Immunotherapy", eds A Sehon and D Kraft, Plenum Press, New York, Chapter 54, pp 381-389 (1996).
Advances in Exp. Med. and Biol., 409, 381-389 (1996).
125. Characterisation of the Human β -Catenin Gene.
 A.L. Norris, A. Bailey, J. Askham, A. Whitehouse, P.M. Clissold, D.M. Meredith and A.F. Markham.
Mammalian Genome, 7, 160-162 (1996).
 126. Increased Elafin Expression in Cystic, Dysplastic and Neoplastic Oral Tissues.
 P.A. Robinson, A.F. Markham, J. Schalkwijk and A.S. High.
J. Oral Path. Med., 25, 135-139 (1996).
 127. Linkage Studies in Non-syndromic Recessive Deafness (NSRD) in a Family Originating from the Mirpur Region of Pakistan Maps DFNB1 Centromeric to D13S175.
 K.A. Brown, A.H. Janjua, G. Karbani, G. Parry, A. Noble, G. Crockford, T. Bishop, V.E. Newton, A.F. Markham and R.F. Mueller.
Human Molecular Genetics, 5, 169-173 (1996).
 128. Investigation of Chromosome 9q22.3-q31 DNA Marker Loss in Odontogenic Keratocysts.
 N.J. Lench, A.S. High, A.F. Markham, W.J. Hume and P.A. Robinson.
Eur. J. Cancer, 32B, 202-206 (1996).
 129. Yeast Artificial Chromosome Cloning of the Abundant Odontogenic Keratocyst Protein, Elafin.
 P.A. Robinson, I.M. Carr, J.P. Leek, A. Bailey, J. Thompson, N.J. Lench, J.F.J. Morrison, A.S. High, W.J. Hume and A.F. Markham.
Arch. Oral Biol., 41, 445-452 (1996).
 130. A Carboxy Terminal Domain of the hMSH-2 Gene Product is Sufficient for Binding to Mismatched Oligonucleotides.
 A. Whitehouse, G.R. Taylor, S.E.V. Phillips, D.M. Meredith and A.F. Markham.
Biochem. Biophys. Res. Comm., 225, 289-295 (1996).
 131. Co-localisation of the Ketohexokinase and Glucokinase Regulator Genes to a 500kb Region of Chromosome 2p23.
 B.E. Hayward, J.A. Fantes, J.P. Warner, S. Intody, J.P. Leek, A.F. Markham and D.T. Bonthron.
Mammalian Genome, 7, 454-458 (1996).
 132. Human Sequences Homologous to the Gene for the Cochlear Protein Ocp-II Do Not Map to Currently Known Non-syndromic Hearing Loss Loci.
 K.A. Brown, J.P. Leek, N.J. Lench, L.L. Moynihan, A.F. Markham and R.F. Mueller.
Ann. Hum. Genet., 60, 385-389 (1996).
 133. Characterisation of a Human Ubiquitin Conjugating Enzyme Gene UBE2L3.
 T.P. Moynihan, J.P. Leek, J. Thompson, H.A. Ardley, N.S. Brindle, A.F. Markham and P.A. Robinson.
Mammalian Genome, 7, 520-525 (1996).
 134. Molecular Analysis of the Presenilin-1 (S182) Gene in "Sporadic" Cases of Alzheimer's Disease: Identification and Characterisation of Unusual Splice Variants.

- R. Anwar, T.P. Moynihan, H. Ardley, N.S. Brindle, P.L. Coletta, N. Cairns, A.F. Markham and P.A. Robinson.
J. Neurochemistry, **66**, 1774-1778 (1996).
135. Vectorette PCR Isolation of Microsatellite Repeat Sequences Using Anchored Dinucleotide Repeat Primers.
N.J. Lench, A.L. Norris, A. Bailey, A. Booth and A.F. Markham.
Nucleic Acids Research, **24**, 2190-2193 (1996).
 136. YAC Clones Which Extend the Human Chromosome 12cen-12q15 Region Contig Map.
S.E. Andersen, N.J. Lench and A.F. Markham.
Mammalian Genome, **7**, 780-784 (1996).
 137. An EST and STS-based YAC Contig Map of Human Chromosome 9q22.3.
N.J. Lench, E.A. Telford, S.E. Andersen, T.P. Moynihan, P.A. Robinson and A.F. Markham.
Genomics, **38**, 199-206 (1996).
 138. Genomic Analysis of Human Multigene Families Using Chromosome-specific Vectorette PCR.
T.P. Moynihan, A.F. Markham and P.A. Robinson.
Nucleic Acids Research, **24**, 4094-4097 (1996).
 139. Carcinoma of the Lung: Warts and All.
A.F. Markham.
Thorax, **51**, 878-880 (1996).
 140. Novel Primer-specific False Terminations During DNA Sequencing Reactions: Danger of Inaccuracy of Mutation Analysis in Molecular Diagnostics.
R. Anwar, A.P. Booth, A.J. Churchill and A.F. Markham.
J. Clin. Path., **49**, 312-315 (1996).
 141. Mutational Analysis of the Nucleotide Binding Domain of the Mismatch Repair Protein hMSH-2.
A. Whitehouse, R. Parmar, J. Deeble, G.R. Taylor, S.E.V. Phillips, D.M. Meredith and A.F. Markham.
Biochem. Biophys. Res. Comm., **229**, 147-153 (1996).
 142. Polymorphism at the Tumour Necrosis Factor Locus and Asthma.
D.A. Campbell, E. Li Kam Wa, J. Britton, S.T. Holgate, A.F. Markham and J.F.J. Morrison.
In "Genetics of Asthma and Atopy", I.P. Hall ed., Karger (Basel), Monographs in Allergy, Vol. 33, pp125-137 (1996).
 143. Physical and genetic mapping of the juvenile-onset primary open-angle glaucoma locus.
A.P. Booth, R. Anwar and A.F. Markham.
Amer. J. Hum. Genet., **59**, 2359, (1996).
 144. Molecular Genetics of the Human Glucokinase Regulator - Fructokinase (*GCKR-KHK*) Region of 2p23.
B.E. Hayward, J.P. Warner, N. Dunlop, J. Fantes, S. Intody, J.P. Leek, A.F. Markham and D.T. Bonthron.
Biochem. Soc. Trans., **25**, 140-145 (1997).

145. The Human gene encoding FKBP-Rapamycin Associated Protein (FRAP) Maps to Chromosomal Band 1p36.2.
N.J. Lench, R. MacAdam and A.F. Markham.
Human Genetics, 99, 547-549 (1997).
146. Alu Repeat Sequences - A Review.
A.J. Mighell, A.F. Markham and P.A. Robinson.
FEBS Letters, 417, 1-5 (1997).
147. Identification and characterisation of a sequence related to human sorbitol dehydrogenase.
I.M. Carr, P.L. Coletta and A.F. Markham.
Eur. J. Biochem., 245, 760-767 (1997)
148. RT-PCR Investigation of Fibronectin mRNA Isoforms in Malignant, Normal and Reactive Oral Mucosa.
A.J. Mighell, J. Thompson, W.J. Hume, A.F. Markham and P.A. Robinson.
Eur. J. Cancer, 33, 155-162 (1997).
149. Human Tenascin-C: Identification of a Novel Type III Repeat in Oral Cancer, and of Novel Splice Variants in Normal, Malignant and Reactive Oral Mucosa.
A.J. Mighell, J. Thompson, W.J. Hume, A.F. Markham and P.A. Robinson.
Int. J. Cancer, 72, 236-240 (1997).
150. Rapid isolation of genomic clones for individual members of human multigene families: Identification of *UBE2L4*, a Novel Member of a Ubiquitin Conjugating Enzyme Dispersed Gene Family.
H.C. Ardley, T.P. Moynihan, J. Thompson, J.P. Leek, , A.F. Markham and P.A. Robinson.
Cytogenet. Cell Genet., 79, 188-192 (1997).
151. Assignment of Indian Hedgehog (*IHH*) to human chromosome bands 2q33-q35 by in situ hybridisation.
J.P. Leek, T.P. Moynihan, R. Anwar, D.T. Bonthron, N.J. Lench and A.F. Markham.
Cytogenet. Cell Genet., 76, 187-188 (1997).
152. The Molecular Mechanisms of Hereditary Disease.
G. Anderson, J.F.J. Morrison and A.F. Markham.
In "A Textbook of Clinical Science: Mechanisms of Disease", eds S. Tomlinson, A. Heagerty and A.R. Weetman, Cambridge University Press, pp 63-95 (1997).
153. Characterization of human SHC p66 isoform cDNA and discrimination from a processed pseudogene mapping to Xq12-13.1.
R. Harun, K.K. Smith, J.P. Leek, A.F. Markham, A. Norris and J.F.J. Morrison.
Genomics, 42, 349-352 (1997).
154. Automated Differential Display Using a Fluorescently-labelled Universal Primer.
N.R. Smith, M. Aldersley, A. Li, T.P. Moynihan, A.F. Markham and P.A. Robinson.
Biotechniques, 23, 274-279 (1997).
155. The cellular distribution of the APC tumour suppressor protein in neuroblastoma cells is regulated by microtubule dynamics.

- E.E. Morrison, J. Askham, A. Norris, P.M. Clissold, P.L. Coletta, A.F. Markham and D.M. Meredith.
Neuroscience, 81, 553-563 (1997).
156. The genetics of primary open-angle glaucoma.
A.P. Booth, A.J. Churchill, R. Anwar, M. Menage and A.F. Markham.
British Journal of Ophthalmology, 81, 409-414 (1997).
 157. The Use of FISH in the Detection of t(2;5)(p23;q35) Translocation in Anaplastic Large Cell Lymphoma.
P.W.M. Johnson, J.P. Leek, K. Swinbank, B. Angus, P. Roberts, A.F. Markham, P.J. Selby and K.A. MacLennan.
Ann. Oncology, 8, 1-4 (1997).
 158. Male pseudohermaphroditism resulting from a Novel Mutation in the Human Steroid 5 α -reductase Type 2 Gene (SRD5A2).
R. Anwar, S.G. Gilbey, J.P. New and A.F. Markham.
J. Clin. Path., 50, 51-53 (1997).
 159. Mapping the minimal domain of hMSH-2 which is sufficient for binding mismatched oligonucleotides.
A. Whitehouse, J. Deeble, G.R. Taylor, P.J. Guillou, S.E.V. Phillips, D.M. Meredith and A.F. Markham
Biochem. Biophys. Res. Comm., 232, 10-13 (1997).
 160. Haemochromatosis gene mutation in liver disease patients.
M.A. Aldersley, P.D. Howdle, J. Wyatt, P.A. Robinson and A. F. Markham.
Lancet, 349, 1025-1026 (1997).
 161. A new mutation in the human lipoprotein lipase gene causing familial hyperchylomicronaemia.
R. Anwar, J.W.L. Puntis and A. F. Markham.
J. Clin. Path., 50, 221-223 (1997).
 162. Rapid determination of the complexity of cDNA bands extracted from DDRT-PCR polyacrylamide gels.
N.R. Smith, A. Li, M. Aldersley, A.S. High, A.F. Markham and P.A. Robinson.
Nucleic Acids Research, 25, 3552-3555 (1997).
 163. From man to molecules and back again.
A.F. Markham and C.J. Hawkey.
Gut, 40, 1-5 (1997).
 164. Analysis of the Mismatch and Insertion/Deletion Binding Properties of *Thermus thermophilus*, HB8, MutS.
A. Whitehouse, J. Deeble, R. Parmar, G.R. Taylor, D.M. Meredith and A.F. Markham.
Biochem. Biophys. Res. Comm., 233, 834-838 (1997).
 165. A new locus for non-syndromal autosomal recessive sensorineural hearing loss (DFNB16) maps to human chromosome 15q21-22.

- D.A. Campbell, D.P. McHale, K.A. Brown, L.M. Moynihan, M. Houseman, G. Karbani, G. Parry, A.H. Janjua, V. Newton, L. Al-Gazali, A.F. Markham, N.J. Lench and R.F. Mueller.
J. Med. Genet., 34, 1015-1018 (1997).
166. Characterisation of *patched* germ line mutations in naevoid basal cell carcinoma syndrome. N.J. Lench, E.A.R. Telford, A.S. High, A.F. Markham, C. Wicking and B.J. Wainwright. Human Genetics, 100, 497-502 (1997).
 167. Genetic Heterogeneity in Schwartz-Jampel syndrome: two families with neonatal Schwartz-Jampel Syndrome do not map to human chromosome 1p34-p36.1. K.A. Brown, L.I. Al-Gazali, L.M. Moynihan, N.J. Lench, A.F. Markham and R.F. Mueller. J. Med. Genet., 34, 685-687 (1997).
 168. Coeliac Disease and Behcet's Disease. M. Aldersley, T. James, J. Wyatt and A.F. Markham British J. Ophthalmology, 81, 710-711 (1997).
 169. Expression of β -Catenin and the adenomatous polyposis coli tumour suppressor protein in mouse neocortical cells in vitro. E.E. Morrison, J. Askham, P.M. Clissold, A.F. Markham and D.M. Meredith. Neuroscience Letters, 235, 129-133 (1997).
 170. The Polymerase Chain Reaction : a Tool for Molecular Medicine. A.F. Markham. In: "Basic Cell and Molecular Biology", British Medical Journal Books, London, 3rd Edition, p.p. 25-41 (1997).
 171. Pax6, Aniridia and Peters' anomaly. A.J. Churchill, R. Anwar and A.F. Markham. Investigative Ophthalmology & Visual Science, 38, 112-113 (1997).
 172. Physical mapping of the dominant optic atrophy gene, OPA1. A.J. Churchill, N.J. Lench and A.F. Markham. Am. J. Hum. Genet., 61, A232, 1348 (1997).
 173. Assignment of the DNA fragmentation factor gene (*DFF*) to human chromosome bands 1p36.2-p36.3 by *in situ* hybridisation. JP Leek, IM Carr, SM. Bell, AF Markham and N.J. Lench. Cytogenet. Cell Genet., 79, 212-214 (1997).
 174. A Trp156Ter Nonsense Mutation in the *PAX 6* Gene in a family with Aniridia. A.J. Churchill, R. Anwar, A.P. Booth and A.F. Markham. Human Mutation, 11, 326-327 (1998).
 175. Identification of a large deletion spanning exons 4 to 11 of the human FXIII A gene, in a Factor XIII deficient family. R. Anwar, K.J.A. Miloszewski and A.F. Markham. Blood, 91, 149-153 (1998).
 176. Connexin 26 mutation in a North African family with congenital, symmetrical, bilateral sensorineural hearing loss.

- N.J. Lench, R. F. Mueller, R.J.H. Smith, P. Williams, I. Schatteman, P. Vande Heyning, G. Van Camp and A.F. Markham
J. Med. Genet., 35, 151-153 (1998).
177. Association study of asthma and atopy traits and chromosome 5q cytokine cluster markers.
A.H. Mansur, D.T. Bishop, A.F. Markham, J. Britton and J.F.J. Morrison.
Clin. Exp. Allergy, 28, 141-150 (1998).
 178. Organisation of the Human Glucokinase Regulator Gene *GCKR*.
N. Dunlop, B.E. Hayward, J.P. Warner, S. Intody, J.P. Leek, A.F. Markham and D.T. Bonthron.
Genomics, 49, 137-142 (1998).
 179. Prostate-specific Membrane Antigen.
B.H. Maraj, P. Whelan and A.F. Markham
British J. Urology, 81, 523-528 (1998).
 180. DNA Mismatch Repair Genes and their association with Colorectal Cancer.
A. Whitehouse, D.M. Meredith and A.F. Markham.
Int. J. Mol. Med., 1, 469-474 (1998).
 181. cDNA cloning, genomic organisation and chromosomal localisation of a novel human gene that encodes a Kinesin-related protein highly similar to mouse Kif3C.
E.A.R. Telford, P. Wightman, J.P. Leek, A.F. Markham, N.J. Lench and D.T. Bonthron.
Biochem. Biophys. Res. Comm., 242, 407-412 (1998).
 182. Failure to reproduce an association between 5-HT_{2A} gene promoter polymorphism and susceptibility to Anorexia Nervosa.
D.A. Campbell, D. Sundaramurthy, A.F. Markham and L. Pieri.
Lancet, 351, 499-500 (1998).
 183. Detailed genetic mapping of a human Prostate-specific membrane antigen gene locus at chromosome 11p11.2.
B.H. Maraj, J.P. Leek, M. Karayi, M.Ali, N.J. Lench and A.F. Markham.
Cytogenet. Cell Genet., 81 3-10 (1998).
 184. A new syndrome of severe mental retardation, spasticity and tapetoretinal degeneration resulting from a recessive chromosome 15q24 mutation.
S.J. Mitchell, D.P. McHale, D.A. Campbell, N.J. Lench, R.F. Mueller, S.E. Bunday and A.F. Markham.
Amer. J. Hum. Genet., 62, 1070-1077 (1998).
 185. Evidence for a common mutation in hereditary pancreatitis.
S.M. Bell, C. Bennett, A.F. Markham and N.J. Lench.
J. Clin. Path., 51, 115-117 (1998).
 186. Fine mapping, genomic organisation and transcript analysis of the human ubiquitin-conjugating enzyme gene UBE2L3.
T.P. Moynihan, C.G. Cole, I. Dunham, L. O'Neil, A.F. Markham and P.A. Robinson.
Genomics, 51, 124-128 (1998).

187. Assignment of GALGT encoding β -1, 4N-acetylgalactosaminyl-transferase (GalNAc-T) and KIF5A encoding neuronal kinesin (D12S1889) to human chromosome band 12q13 by assignment to ICI YAC26EG10 and in situ hybridization.
P.J. Hamlin, P.F. Jones, J.P. Leek, K. Bransfield, N.J. Lench, M.A. Aldersley, P.D. Howdle, A.F. Markham and P.A. Robinson.
Cytogenet. Cell Genet., **82**, 267-268 (1998).
188. Novel splicing mutations in the human Factor XIII A gene each producing multiple mutant transcripts of varying abundance.
R. Anwar, K.J.A. Miloszewski and A.F. Markham.
Thrombosis and Haemostasis, **79**, 1151-56 (1998).
189. Identification of mutations in the Connexin 26 gene that cause autosomal recessive non-syndromic hearing loss.
D.A. Scott, M.L. Kraft, R. Carmi, A. Ramesh, K. Elbedour, Y. Yairi, S.R.S. Srikumari, S.S. Rosengren, A.F. Markham, R. F. Mueller, N.J. Lench, G. Van Camp, R.J.H. Smith and V.C. Sheffield.
Human Mutation, **11**, 387-394 (1998).
190. Autozygosity mapping to chromosome 11q25 of a rare autosomal recessive syndrome causing histiocytosis, joint contractures and sensorineural deafness.
L.M. Moynihan, S.E. Bunday, D. Heath, E.L. Jones, D.P. McHale, R.F. Mueller, N.J. Lench and A.F. Markham.
Amer. J. Hum. Genet. **62**, 1123-1129 (1998).
191. The CD4⁺ subset of T lymphocytes is a site of steroid resistance in asthma.
F. Syed, B. Bingham, M. Johnson, A.F. Markham and J.F.J. Morrison.
Q.J. Medicine, **91**, 567-572 (1998).
192. Prostate-specific membrane antigen expression in the duodenum: implications in coeliac disease and prostate cancer immunotherapy.
B.H. Maraj, M.A. Aldersley and A.F. Markham.
Lancet, **351**, 1559-1560 (1998).
193. *PAX-6* is normal in most cases of Peter's anomaly.
A.J. Churchill, A.P. Booth, R. Anwar and A.F. Markham.
Eye, **12**, 299-303 (1998).
194. Splicing and missense mutations in the human FXIII A gene causing FXIII deficiency: effects of these mutations on FXIII A RNA processing and protein structure.
R. Anwar, L. Gallivan, K.J.A. Miloszewski and A.F. Markham.
British J. Haematology, **103**, 425-428 (1998).
195. Genetic Heterogeneity and HOMOG analysis in British Malignant Hyperthermia Families.
R. Robinson, J.L. Curran, S.P. West, P.J. Halsall, F.R. Ellis, A.F. Foroughmand, A.D. Stewart, A.F. Markham and P.M. Hopkins.
J. Med. Genet., **35**, 196-201 (1998)
196. Primary Autosomal Recessive Microcephaly (MCPH1) maps to Chromosome 8p23.

- A.P. Jackson, D.P. McHale, D.A. Campbell, H. Jafri, Y. Rashid, J.Mannan, G. Karbani, P. Corry, M.I. Levene, R.F. Mueller, A.F. Markham, N.J. Lench and C.G. Woods.
Amer. J. Hum. Genet., 63, 541-547 (1998).
197. Assignment of the ubiquitin conjugating enzyme gene, *UBE2G2*, to human chromosome band 21q22.3 by *in situ* hybridisation.
S.A. Rose, J.P. Leek, T.P. Moynihan, H.C. Ardley, A.F. Markham and P.A. Robinson.
Cytogenet. Cell Genet., 83, 98-99 (1998).
 198. EB1, a protein which interacts with the APC tumour suppressor, is associated with the microtubule cytoskeleton throughout the cell cycle.
E.E. Morrison, B.N. Wardleworth, J.M. Askham, D.M. Meredith and A.F. Markham.
Oncogene, 17, 3471-3477 (1998).
 199. Assignment of herpesvirus-associated ubiquitin-specific protease gene, *HAUSP*, to human chromosome band 16p13.3 by *in situ* hybridisation.
P.A. Robinson, P. Lomonte, J.P. Leek, A.F. Markham and R.D. Everett.
Cytogenet. Cell Genet., 83, 100-101 (1998).
 200. Fine mapping of 12 previously unassigned EST clones in the familial Alzheimer's disease (FAD3) region of chromosome 14q24.3.
H.C. Ardley, P.A. Robinson, and A.F. Markham.
Cytogenet. Cell Genet., 82, 107-109 (1998).
 201. Structure and evolutionary characterisation of the human sorbitol dehydrogenase gene duplication.
I.M. Carr, A. Whitehouse, P.L. Coletta and A.F. Markham.
Mammalian Genome, 9, 1042-1048 (1998).
 202. Fine mapping of the Human 5-*HTR2a* gene to chromosome 13q14 and identification of two highly polymorphic linked markers suitable for association studies in psychiatric disorders.
D. Campbell, D. Sundaramurthy, A.F. Markham and L.F. Pieri.
Genetic Testing, 1, 297-300 (1998).
 203. Haemochromatosis and Type 2 diabetes.
M.A. Aldersley, V. Aligar, P.D. Howdle and A.F. Markham.
Lancet, 352, 1067-1068 (1998).
 204. Cytogenetics and the surgeon: an invaluable tool in diagnosis, prognosis and counselling of patients with solid tumours.
G. Humphrey, R. Squire, M. Lansdown, A.F. Markham and K.A. MacLennan.
Br. J. Surgery, 85, 725-734 (1998).
 205. Assignment of *UBE2D1* to human chromosome 10q11.2-21 by *in situ* hybridisation.
P.A. Robinson, J.P. Leek, H.C. Ardley, S.A. Rose and A.F. Markham.
Cytogenet. Cell Genet., 83, 247-249 (1998).
 206. Assignment of the melanocortin 4 receptor (*MC4R*) gene to human chromosome band 18q22 by *in situ* hybridisation and radiation hybrid mapping.
D. Sundaramurthy, D.A. Campbell, J.P. Leek, A.F. Markham and L.F. Pieri.
Cytogenet. Cell Genet., 82, 97-99 (1998).

207. Cyclo-oxygenase2 expression is limited to lamina propria cells in the intestinal epithelium of *min* mice.
M.A. Hull, J.K. Booth, N. Scott, A. Tisbury, P.M. Clissold, A.F. Markham and P.L. Coletta.
British J. Cancer, 79, 1399-1405 (1999).
208. A gene for autosomal recessive symmetrical spastic cerebral palsy maps to chromosome 2q24-q25.
D.P. McHale, S. Mitchell, , S.P. Bunday, L.L. Moynihan, D.A. Campbell, C.G. Woods, N.J. Lench, R.F. Mueller, and A.F. Markham.
Amer. J. Hum. Genetics, 64, 526-532 (1999).
209. Association between a marker in the *UCP-2/UCP-3* gene cluster and genetic susceptibility to Anorexia Nervosa.
D.A. Campbell, D. Sundaramurthy, A.F. Markham and L.F. Pieri.
Mol. Psychiatry, 4, 68-71 (1999).
210. The gene product encoded by ORF57 of Herpesvirus saimiri regulates the redistribution of the splicing factor, SC-35.
M. Cooper, D.J. Goodwin, K.T. Hall, A.J. Stevenson, A.F. Markham, D.M Meredith, and A. Whitehouse
J. Gen. Virol, 80, 297-300 (1999).
211. Coagulation Factor XIII specific activity is variable in the normal population.
R. Anwar, L. Gallivan, S.E. Edmonds and A.F. Markham.
Blood, 93, 897-905 (1999).
212. Assessment of *Herpesvirus saimiri* as a Potential Human Gene Therapy Vector.
A.J. Stevenson, M.M. Cooper, J.C. Griffiths, P.C. Gibson, A. Whitehouse, E.F. Jones, A.F. Markham, S.E. Kinsey and D.M. Meredith.
J. Med. Virol., 57, 269-277 (1999).
213. Suggestive evidence for genetic linkage between IgE phenotypes and Chromosome 14q markers.
A.H. Mansur, D.T. Bishop, J. Wilkinson, N.E. Morton, S.T. Holgate, A.F. Markham and J.F.J. Morrison.
Amer. J. Resp. Crit. Care Med., 159, 1796-1802 (1999).
214. Chromosomal localisation of the gene for Angiopoietin-4, a further ligand for the Tie2 receptor tyrosine kinase to 20p13.
K. Grosios, J.P. Leek, A.F. Markham, G.D. Yancopoulos and P.F. Jones.
Cytogenet. Cell Genet., 84, 118-120 (1999).
215. Characterisation of the mouse ubiquitin-conjugating enzyme gene *UbcM4*.
T.P. Moynihan, U. Nuber, H.C. Ardley, M. Scheffner, A.F. Markham and P.A. Robinson.
Mammalian Genome, 10, 977-982 (1999).
216. Prostate-specific membrane antigen (*FOLH1*): recent advances in characterising this putative prostate cancer gene.
B.H. Maraj and A.F. Markham.
Prostate Cancer and Prostatic Diseases, 2, 180-185 (1999).
217. A locus for isolated Cleft Palate on Human Chromosome 2q32.

- C.M. Brewer, J.P. Leek, A.J. Green, S. Holloway, D.T. Bonthron, D.R. FitzPatrick and A.F. Markham.
Amer. J. Hum. Genet., 65, 387-397 (1999).
218. The ubiquitin conjugating enzymes UbcH7 and Ubc H8 interact with RING-finger proteins including the human homologue of Ariadne.
T.P. Moynihan, H.C. Ardley, U. Nuber, S.A. Rose, P.F. Jones, M. Scheffner, A.F. Markham and P.A. Robinson.
J.Biol.Chem., 274, 30963-30968 (1999).
 219. A second locus for autosomal recessive primary microcephaly (MCPH2) maps to chromosome 19q13.1-13.2.
E. Roberts, A.P. Jackson, A.C. Caradice, V.J. Deeble, A.F. Markham and C.G. Woods.
Eur. J. Hum. Genet., 7, 815-820 (1999).
 220. Assignment of the murine *Apc-2* gene to mouse chromosome band 10B5-C2 by in situ hybridisation.
S.M. Bell, W.K. Lam, I.M. Carr, E. Cartwright, K. Pinchin, S. Wedgewood, A.F. Markham and P.L. Coletta.
Cytogenet. Cell Genet., 86, 81-82 (1999).
 221. (CCR7) EBI-1 receptor down regulation in asthma : use of high density array hybridisation to detect differential gene expression in human CD4 + T lymphocytes.
F. Syed, S.J. Blakemore, D.M. Wallace, M.K. Trower, M. Johnson, A.F. Markham and J.F.J. Morrison.
Q.J. Medicine., 92, 463-471 (1999).
 222. The candidate tumour suppressor gene, *ING-1*. is retained in colorectal carcinomas.
A.I. Sarela, S.M. Farmery, A.F. Markham and P.J. Guillou.
Eur. J. Cancer, 35, 1264-1267 (1999).
 223. The Leu564 factor XIIIa variant induces significantly lower plasma factor XIII levels compared to the Pro564 variant.
L. Gallivan, A.F. Markham and R. Anwar.
Thrombosis and Haemostasis, 82, 1368-70 (1999).
 224. Isolation and characterisation of a cDNA encoding the precursor for a novel member of the Acyl-CoA Dehydrogenase gene family.
E.A. Telford, L.M. Moynihan, A.F. Markham and N.J. Lench.
Biochim.Biophys.Acta, 1446, 371-376 (1999).
 225. Identification of multiple candidate genes for inflammatory bowel disease susceptibility using high density transcript mapping in the IBDF2 locus on chromosome 12q.
P.J. Hamlin, P. Komolmit, K. Bransfield, P.F. Jones, N.R. Smith, M.A. Aldersley, P.D. Howdle, A.F. Markham and P.A. Robinson.
Gastroenterology, 117, 1029-1032 (1999).
 226. Loss-of-function mutations in the Cathepsin C gene result in periodontal disease and palmoplantar keratosis (Papillon-Lefèvre syndrome).

- C. Toomes, J. James, A.J. Wood, C.L. Wu, D. McCormick, N.J. Lench, C. Hewitt, L. Moynihan, E. Roberts, C.G. Woods, A.F. Markham, A.P. Read, P. Sloan, M.J. Dixon and N.S. Thakker.
Nature Genetics, **23**, 421-425 (1999).
227. The activation domain of the Herpesvirus saimiri R protein interacts with the TATA-binding protein.
K.T. Hall, A.J. Stevenson, D.J. Goodwin, P.C. Gibson, A.F. Markham and A. Whitehouse.
J. Virology, **73**, 9756-9763 (1999).
 228. The ORF57 gene product of Herpesvirus Saimiri shuttles between the nucleus and cytoplasm and is involved in viral nuclear export.
D.J. Goodwin, K.T. Hall, A.J. Stevenson, A.F. Markham and A. Whitehouse.
J. Virology, **73**, 10519-10524 (1999).
 229. Segregation of malignant hyperthermia, central core disease and chromosome 19 markers.
J.L. Curran, W.J. Hall, P.J. Halsall, P.M. Hopkins, D.E. Iles, A.F. Markham, S.H. McCall, R.L. Robinson, S.P. West, L.R. Bridges and F.R. Ellis.
British J. Anaesthesia, **83**, 217-222 (1999).
 230. Tumour suppressor genes and oncogenes in prostate cancer.
A. Bailey and A.F. Markham.
In: "Prostate Cancer", eds. P. Lalani and H. Land, Academic Press, New York, Chapter 14, pp. 200-220 (2000).
 231. Truncated APC tumour suppressor protein can undergo tyrosine phosphorylation.
A.L. Norris, P.M. Clissold, J.M. Askham, E.E. Morrison, P. Moncur, S.H. McCall, P.L. Coletta, D.M. Meredith and A.F. Markham.
Eur. J. Cancer, **36**, 525-532 (2000).
 232. Identification of a polymorphic marker suitable for loss of heterozygosity studies close to the putative *KAI-1* prostatic cancer metastasis suppressor gene.
B.H. Maraj, J.P. Leek, I.M. Carr and A.F. Markham.
European Urology, **37**, 228-233 (2000).
 233. Localisation of Cyclooxygenase-2 in human sporadic colorectal adenomas.
K.S. Chapple, A. Tisbury, G. Hawcroft, E.J. Cartwright, D.J. Scott, C. Bonifer, N. Scott, A.C.J. Windsor, P.J. Guillou, A.F. Markham, P.L. Coletta and M.A. Hull.
Amer. J. Pathology, **156**, 545-553 (2000).
 234. Sequencing of the Tissue Transglutaminase gene in Coeliac Disease Patients does not detect polymorphism.
M.A. Aldersley, J.P. Hamlin, P.F. Jones, P.D. Howdle, P.A. Robinson and A.F. Markham.
Scand. J. Gastroenterol., **35**, 61-63 (2000).
 235. Analysis of the serotonin transporter gene linked polymorphism (5-HTTLPR) in anorexia nervosa.
D. Sunderamurthy, L.F. Pieri, A.F. Markham and D.A. Campbell.
Amer. J. Med. Genet., **96**, 53-55 (2000).
 236. A gene for ataxic cerebral palsy maps to chromosome 9p12-q12.
D. McHale, A.P. Jackson, D.A. Campbell, M.I. Levene, P. Corry, C.G. Woods, N.J. Lench,

- R.F. Mueller and A.F. Markham.
Eur.J.Hum.Genet., 8, 267-272 (2000).
237. Current status of linkage studies in hereditary prostate cancer.
M. Karayi, D.E. Neal and A.F. Markham.
British Journal of Urology, 86, 659-669 (2000).
238. Prenatal diagnosis of Aniridia.
A.J. Churchill, I.M. Hanson and A.F. Markham.
Ophthalmology, 107, 1153-1156 (2000).
239. Expression of the anti-apoptosis gene, *Survivin*, predicts death from recurrent colorectal carcinoma.
A.I. Sarela, R.C.A. Macadam, S.M. Farmery, A.F. Markham and P.J. Guillou.
Gut, 46, 645-650 (2000).
240. Lack of linkage between chromosome 5q23-33 markers and IgE/bronchial hyperreactivity in 67 Scottish families.
A.H. Mansur, G. Christie, A. Turner, D.T. Bishop, A.F. Markham, P. Helms and J.F.J. Morrison.
Clin. Exp. Allergy, 30, 954-961 (2000).
241. Regulation and Function of the Interaction between the APC Tumour Suppressor Protein and EB1.
J.M. Askham, P. Moncur, A.F. Markham and E.E. Morrison.
Oncogene, 19, 1950-58 (2000).
242. Vertebrate Pseudogenes – a review.
A.J. Mighell, N.R. Smith, P.A. Robinson and A.F. Markham
FEBS Letters, 468, 109-114 (2000).
243. Transcriptional regulation of the human ubiquitin-conjugating enzyme gene family *UBE2L*.
H.C. Ardley, T.P. Moynihan, A.F. Markham and P. A. Robinson.
Biochim. Biophys. Acta, 1491, 57-64 (2000).
244. Genetic screening in a large family with juvenile onset primary open-angle glaucoma.
A.P. Booth, R. Anwar, H. Chen, A.J. Churchill, J. Jay, J. Polansky, T. Nguyen and A.F. Markham.
Brit. J. Ophthalmol., 84, 722-726 (2000).
245. A Herpesvirus saimiri based gene therapy vector with potential for use in cancer immunotherapy.
A. J. Stevenson, E. Frolova-Jones, K.T. Hall, S.E. Kinsey, A. Whitehouse, A.F. Markham and D. M. Meredith.
Cancer Gene Therapy, 7, 1077-1085 (2000).
246. Analysis of gene expression in an Herpesvirus saimiri stably transduced human cell line.
K.T. Hall, M.S. Giles, D.J. Goodwin, M.A. Calderwood, I.M. Carr, A.J. Stevenson, A.F. Markham and A. Whitehouse.
J. Virology, 74, 7331-7337 (2000).
247. Specific oncolytic activity of Herpesvirus saimiri in human pancreatic cancer cells.
A.J. Stevenson, M.S. Giles, K.T. Hall, D.J. Goodwin, M.A. Calderwood, A.F. Markham and

- A. Whitehouse.
Br. J. Cancer, **83**, 329-332 (2000)
248. Genomic organisation of the human ubiquitin-conjugating enzyme gene, *UBE2L6* on chromosome 11q12.
H.C. Ardley, S.A. Rose, N. Tan, J.P. Leek, A.F. Markham and P.A. Robinson
Cytogenet. Cell Genet., **89**, 137-140 (2000).
249. The carboxyterminus of the HVS ORF57 gene contains domains that are required for transactivation and transrepression.
D.J. Goodwin, K.T. Hall, M.S. Giles, M.A. Calderwood, A.J. Stevenson, A.F. Markham and A. Whitehouse.
J. Gen. Virol., **81**, 2253-2265 (2000).
250. A novel mutation in the mitochondrial tRNA^{Ser} (UCN) gene in a family with maternally inherited hearing impairment.
T. Hutchin, M. Parker, I.D. Young, L. Pulleyn, J. Deeble, N.J. Lench, R.F. Mueller and A.F. Markham.
J. Med. Genet., **37**, 692-694 (2000).
251. Ser295Arg is the first Factor XIII deficiency causing mutation to be found in the active site-containing exon 7 of the FXIIIa gene.
R. Anwar, L. Gallivan, K.J.A. Miloszewski and A.F. Markham.
Thrombosis and Haemostasis, **84**, 591-594 (2000).
252. Evidence for a role of HLA DRB1 and DQB1 alleles in the control of IgE levels, strengthened by interacting TCR A/D marker alleles.
A.H. Mansur, G. Williams, D.T. Bishop, A.F. Markham, S. Lewis, J. Britton and J.F.J. Morrison.
Clin. Exp. Allergy, **30**, 1371-1378 (2000).
253. Presence of *REG* gene transcripts predicts outcome in early colorectal cancer.
R.C.A. Macadam, S.M. Farmery, P.L. Coletta, K. A. MacLennan, P.A. Robinson, A.F. Markham and P.J. Guillou.
British J. Cancer, **83**, 188-195 (2000).
254. Fc gamma receptor IIIA is associated with rheumatoid arthritis through an interaction with HLA-DRB1 in two distinct racial groups.
A.W. Morgan, B. Griffiths, F. Ponchel, M. Ali, P. Gardner, D. Situnayake, H.C. Gooi, A.F. Markham, P. Emery and J.D. Isaacs.
Arthritis and Rheumatism, **43**, 2328-2334 (2000).
255. A novel translocation of the *BCL-10* gene in a case of MALT lymphoma.
R. Achuthan, S.M. Bell, J.P. Leek, P. Roberts, K. Horgan, A.F. Markham, P.J. Selby and K.A. MacLennan.
Genes, Chromosomes and Cancer, **29**, 347-349 (2000).
256. Characterisation of the Herpesvirus saimiri ORF73 gene product.
K.T. Hall, M.S. Giles, D.J. Goodwin, M.A. Calderwood, A.F. Markham and A. Whitehouse.

- J.Gen.Virol., **81**, 2653-2658 (2000).
257. Characterisation of the human and mouse orthologues of the *Drosophila ariadne* gene..
N.G.S. Tan, H.C. Ardley, S.A. Rose, J.P. Leek, A.F. Markham and P.A. Robinson.
Cytogenet. Cell Genet., **90**, 242-246 (2000).
 258. A new locus for autosomal recessive non-syndromal sensorineural hearing impairment (DFNB27) on chromosome 2q23-q31 is not allelic to DFNA16.
L.J. Pulleyn, A.P. Jackson, E. Roberts, A. Carradice, C. Muxworthy, M. Houseman, L.I. Al-Gozali, N.J. Lench, A.F. Markham and R.F. Mueller.
Eur.J.Hum.Genet., **8**, 991-993 (2000).
 259. The influence of Factor XIII A missense, promoter (G/A-246) and intronic splicing mutations on plasma Factor XIII levels.
R. Anwar, L. Gallivan, K.J.A. Miloszewski and A.F. Markham.
Haemostasis, **30**, 29-31 (2000).
 260. Identification and Characterisation of a novel brain-selective transcript of the *Apc* tumour suppressor gene.
S. Wedgewood, K.M. Pinchin, W.K. Lam, E.J. Cartwright, A.F. Markham and P.L. Coletta.
Mammalian Genome, **11**, 1150-1154 (2000).
 261. Rheumatoid arthritis synovial T-cells regulate expression of several genes associated with antigen-induced anergy.
M. Ali, F. Ponchel, M.J.D. Francis, F.C. Lancaster, X. Wu, A. Verhoeff, A.W. Boylston, D.J. Veale, P. Emery, A.F. Markham, J.R. Lamb and J.D. Isaacs.
J. Clin. Invest., **107**, 519-528 (2001).
 262. Identification of a new Leu354 Pro Mutation responsible for Factor XIII deficiency.
R. Anwar, L. Gallivan, C.H. Trinh, F.G. Hill, K.J.A. Miloszewski and A.F. Markham.
Eur. J. Haematology, **66**, 133-136 (2001).
 263. Maternally inherited hearing impairment and a family with the mitochondrial DNA A7445G mutation.
T.P. Hutchin, N.J. Lench, S. Arbruzova, A.F. Markham and R.F. Mueller.
Eur.J.Hum.Genet., **9**, 56-58 (2001).
 264. Application of differential display to immunological research.
M. Ali, A.F. Markham and J.D. Isaacs.
Journal of Immunological Methods, **250**, 29-43 (2001).
 265. The inhibitor of apoptosis protein, Survivin, predicts survival following curative resection of Stage II colorectal carcinomas.
A.I. Sarela, N. Scott, J. Ramsdale, A.F. Markham and P.J. Guillou.
Annals of Surgical Oncology, **8**, 305-310 (2001).
 266. *Sox-9* has a conserved male-specific role in temperature-dependent sex determination in the Leopard gecko, *Eublepharis macularius*.
E.A. Valleley, N.J. Croft, A.F. Markham and P.L. Coletta.
J. Exp. Zoology, **291**, 85-91 (2001).

267. Features of the Parkin/Ariadne-like ubiquitin ligase, HHARI, which regulate its interaction with the ubiquitin-conjugating enzyme UbcH7.
H.C. Ardley, H.G.S. Tan, S.A. Rose, A.F. Markham and P.A. Robinson.
J.Biol.Chem., 276, 19640-19647 (2001).
268. Spectrum, frequency and penetrance of *OPA1* mutations in dominant optic atrophy.
C. Toomes, N.J. Murton, D.D. Mackey, R.A. Newbury-Edob, C.P. Bennett, C.J. Vize, S.P. Desai, G.C.M. Black, N. Patel, M. Teimory, A.F. Markham, C.F. Inglehearn and A.J. Churchill.
Human Molecular Genetics 10, 1369-1378 (2001).
269. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease.
A.R. Curtis, C. Fey, C.M. Morris, L.A. Bindoff, P.G. Ince, P.F. Chinnery, A. Coulthard, M.J. Jackson, A.P. Jackson, D.P. McHale, A.F. Markham, D. Bates, A. Curtis, J. Burn.
Nature Genetics, 28, 350-354 (2001).
270. Mutations in the pre-mRNA splicing factor gene *PRPC8* cause autosomal dominant Retinitis pigmentosa (RP13).
A.B.McKie, J.C. McHale, T.J. Keen, E.E. Tarttelin, R. Goliath, J. Greenberg, R.S. Ramesar, F.P.M. Cremers, C.B. Hoyng, J.J.C. van Lith-Verhoeven, D.A. Mackey, S.S. Bhattacharya, A.C. Bird, A.F. Markham and C.F. Inglehearn.
Human Molecular Genetics, 10, 1555-1562 (2001).
271. Genetic events during the transformation of a tamoxifen-sensitive human breast cancer cell line into a drug resistant clone : a study using comparative genomic hybridisation, conventional cytogenetics and chromosome painting.
R. Achuthan, S.M. Bell, P. Roberts, J.P. Leek, K. Horgan, A.F. Markham, K.A. MacLennan and V.E. Speirs.
Cancer Genet. Cytogenet., 130, 166-172 (2001).
272. Expression of the Sonic hedgehog receptor 'PATCHED' in basal cell carcinomas and odontogenic keratocysts.
W. Zedan, P.A. Robinson, A.F. Markham and A.S. High.
J. Pathology, 194, 472-476 (2001).
273. Lack of inducible nitric oxide synthase promotes intestinal tumourigenesis in the Apc (min) mouse model of familial adenomatous polyposis.
D. Scott, M.A. Hull, E. Cartwright, W.K. Lam, A. Tisbury, A.F. Markham, C. Bonifer and P.L. Coletta.
Gastroenterology, 21, 889-899 (2001).
274. Conserved genomic structures between the human angiopoietins 1, 2 and 4 and polymorphism in angiopoietin 2.
K. Grosios, E.G. Ward, A.F. Markham and P.F. Jones.
Cytogenet. Cell Genet., 94, 147-154 (2001).
275. In vivo episomal maintenance of a Herpesvirus saimiri-based gene delivery vector.
P.G. Smith, P.L. Coletta, A.F. Markham and A. Whitehouse.
Gene Therapy, 8, 1762-1769 (2001).

276. Expression of survivin, a novel anti-apoptosis and cell cycle regulatory protein, in periampullary pancreatic adenocarcinoma.
A.I. Sarela, C.S. Verbeke, J. Ramsdale, C.L. Davies, A.F. Markham and P.J. Guillou.
Br. J. Cancer, **86**, 886-892 (2001).
277. *BCL10* in malignant lymphomas: an evaluation using fluorescent *in situ* hybridisation.
R. Achutan, S.M. Bell, I.M. Carr, J.P. Leek, P. Roberts, K. Horgan, P.J. Selby, A.F. Markham and K.A. MacLennan.
J. Pathology, **196**, 59-66 (2002).
278. A family study and the natural history of prenatally-detected unilateral multicystic dysplastic kidney.
R.A. Belk, D.F.M. Thomas, R.F. Mueller, P. Godbole, A.F. Markham and M.J. Weston.
J. Urology, **167**, 666-669 (2002).
279. Indomethacin induces differential expression of β -catenin, γ -catenin and β -catenin/TCF/LEF target genes in human colorectal cancer cells.
G. Hawcroft, M.D'Amico, C. Albanese, A.F. Markham, R.G. Pestell and M.A. Hull.
Carcinogenesis, **23**, 107-114 (2002).
280. Delayed umbilicus bleeding – a presenting feature for factor XIII deficiency: clinical features, genetics and management.
R. Anwar, A. Minford, L. Gallivan, C.H. Irish and A.F. Markham.
Paediatrics, **109**, E32 (2002).
281. Mutations in a protein target of the Pim-1 kinase associated with the RP-9 form of autosomal dominant retinitis pigmentosa.
T.J. Keen, M.M. Himms, A.B. McKie, A.T. Moore, R.M. Doran, D.A. Mackey, D.C. Mansfield, R.F. Mueller, S.S. Bhattacharya, A.C. Bird, A.F. Markham and C.F. Inglehearn.
Eur. J. Hum. Genet., **10**, 245-249 (2002).
282. Identification of Microcephalin, a protein implicated in the determining the size of the human brain.
A.P. Jackson, H. Eastwood, S.M. Bell, J. Adu, C. Toomes, I.M. Carr, E. Roberts, D.J. Hampshire, Y.J. Crow, A.J. Mighell, G. Karbani, H. Jafri, Y. Rashid, R.F. Mueller, A.F. Markham and C.G. Woods.
Amer. J. Hum. Genet., **71**, 136-142 (2002).
283. Haploinsufficiency is the cause of disease in dominant optic atrophy patients with mutations in the *OPA1* gene.
N.J. Marchbank, J.E. Craig, J.P. Leek, M. Toohey, A.J. Churchill, A.F. Markham, D.A. Mackey, C. Toomes and C.F. Inglehearn.
J. Med. Genet., **39**, 47-55 (2002).
284. Paracrine cyclooxygenase-2-mediated signalling by macrophages promotes tumorigenic progression of intestinal epithelial cells.
C.W.S. Ko, K.S. Chapple, G. Hawcroft, P.L. Coletta, A.F. Markham and M.A. Hull.
Oncogene, **21**, 7175-7186 (2002).
285. Dysregulated lymphocyte proliferation and differentiation in patients with Rheumatoid Arthritis.

- F. Ponchel, A.W. Morgan, S.J. Bingham, M. Quinn, A. Brown, C.A. Lawson, Mr. Buch, J. Moore, R.J. Verburg, J.A. Henwood, S.H. Douglas, A. Masurel, P. Conaghan, D. Ma, M. Gesindl, A.F. Markham, P. Emery, J.M. van Laar and J.D. Isaacs.
Blood, 100, 4550-56 (2002).
286. Abnormal Spindle gene is a major determinant of human cerebral cortex size.
J. Bond, E. Roberts, G.H. Mochida, D. Hampshire, S. Scott, J.M. Askham, K. Springell, M. Mahadevan, Y. Crow, C.A. Walsh, A.F. Markham and C.G. Woods.
Nature Genetics, 32, 316-320 (2002).
 287. Isolation and Characterisation of the human bone marrow multipotential mesenchymal osteoprogenitor cell.
E.A. Frolova-Jones, S.E. Kinsey, R.A. Jones, A. Jack, L. Straszynski, A. Rawstron, D.M. Meredith, A.F. Markham, P. Emery and D. McGonagle.
Arthritis & Rheumatism, 46, 3349-60 (2002).
 288. Expression of m0b1, a novel atypical 73 amino acid K50-homeodomain protein, during mouse development.
J. Adu, F.T. Leong, N.R. Smith, J.P. Leek, A.F. Markham, P.A. Robinson and A.J. Mighell.
Mechanisms of Development, 119, 43-47 (2002).
 289. FcγRIIIA-158V is associated with Rheumatoid Arthritis : Implications for RA pathogenesis.
A.W. Morgan, V.H. Keyte, S.J. Babbage, J.I. Robinson, F. Ponchel, B.B. Bhakta, S.J. Bingham, M.H. Buch, P.G. Conaghan, A. Gough, M. Green, C.A. Lawson, C.T. Pease, A.F. Markham, W.E. R. Ollier, P. Emery, J. Worthington and J.D. Isaacs.
Rheumatology, 42, 528-533 (2003).
 290. Identification by FISH of micro-deletions at 1p36 in lymphomas previously undetected on cytogenetic analysis.
R. Achuthan, I.M. Carr, J.P. Leek, D. Hodge, S.M. Bell, P. Roberts, K. Horgan, D.T. Bonthron,
P.J. Selby, K.E. MacLennan and A.F. Markham.
Cancer Genet. Cytogenet., 142, 46-50, (2003).
 291. The presence of multiple regions of homozygous deletion at the *CSMD1* locus in oral squamous cell carcinoma question the role of *CSMD1* in head and neck carcinogenesis..
C. Toomes, A.P. Jackson, K. Maguire, A.J. Wood, S.M. Gollin, C.S. Ishwad, I.C. Paterson, S.S. Prime, E.K. Parkinson, S.M. Bell, C.G. Woods, A.F. Markham, R. Oliver, R. Woodward, P. Sloan, M.J. Dixon, A.P. Read and N.S. Thakker.
Genes, Chromosomes and Cancer, 37, 132-140 (2003).
 292. Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridisation.
J. Dent, G.D. Hall, N. Wilkinson, T.J. Perren, I. Richmond, A.F. Markham and S.M. Bell.
British Journal of Cancer, 88, 1578-83 (2003).
 293. Overexpression of transcripts containing Line-1 in the synovia of patients with rheumatoid arthritis.
M. Ali, D.J. Veale, R.J. Reece, M. Quinn, K. Henshaw, E.D. Zanders, A.F. Markham, P. Emery and J.D. Isaacs.
Ann.Rheumatic Diseases, 62, 663-666 (2003).
 294. Identification of STAB2 as the cleft palate gene on 2q32-q33.

- D.R. Fitzpatrick, I.M. Carr, L. McLaren, J.P. Leek, P. Wightman, K. Williamson, P. Gautier, N. McGill, C. Hayward, H. Firth, A.F. Markham, J.A. Fantes and D.T. Bonthron.
Human Molecular Genetics, 12, 2491-2501 (2003).
295. Reduced expression of oestrogen receptor β in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model.
G.P. Skliris, K. Munot, S.M. Bell, P.J. Carder, S. Lane, K. Horgan,
M.R.J. Lansdown, A.T. Parkes, A.M. Hanby, A.F. Markham and V.E. Speirs.
J. Pathology, 201, 213-220 (2003).
 296. Inhibition of proteosomal activity causes inclusion formation in neuronal and non-neuronal cells over-expressing Parkin.
H.C. Ardley, G.B. Scott, S.A. Rose, N.G.S. Tan, , A.F. Markham and P.A. Robinson.
Mol. Biol. Cell, 14, 4541-4556 (2003)
 297. The UbcH7 interacting protein, HHARI, promotes binding of the e1F4E homologous protein, 4EHP, to the 7-methyl GTP cap of mRNA.
N.G.S. Tan, H.C. Ardley, G.B. Scott, S.A. Rose, A.F. Markham and P.A. Robinson.
FEBS Letters, 554, 501-504. (2003).
 298. Challenges facing Cancer Research UK.
A.F. Markham
Eur. J. Cancer, 39, 2251-2252 (2003).
 299. Tumours of the Gastrointestinal Tract.
A.F. Markham, IC Talbot and C.B. Williams.
In "The Oxford Textbook of Medicine", 4th Edition, eds. D.A. Worrell, T.M. Cox,
J.D. Firth and E.J. Benz, Oxford University Press, Vol 2, Chapter 14.15, pp 637-651(2003).
 300. Real-time PCR based on SYBR-green fluorescence: an alternative to the TaqMan assay for quantification of gene rearrangements, amplifications and microdeletions.
F. Ponchel, C. Toomes, K. Bransfield, F.T. Leong, S.H. Douglas, S.M. Bell, A.J. Mighell,
P.A. Robinson, C.F. Inglehearn, J.D. Isaacs and A.F. Markham.
BMC Biotechnology, 3, 18-28 (2003).
 301. Lymphodepletion in the *Apc*^{Min} mouse model of intestinal tumorigenesis.
P.L. Coletta, AM Müller, E.A. Jones, B. Mühl, S. Holwell, D. Clarke, JL Meade,
G.P. Cook, G. Hawcroft, F. Ponchel, W.K. Lam, K.A. MacLennan, M.A. Hull, C. Bonifer and
A.F. Markham.
Blood, 103, 1050-1058 (2004).
 302. PRELI is located within an evolutionarily conserved gene cluster on chromosome 5q34-q35 and encodes a novel mitochondrial protein.
E.J. Fox, S.A. Stubbs, J.P. Leek, A.F. Markham and S.C. Wright.
Biochem. Journal, 378, 817-825 (2004).
 303. Linkage/association study for a locus mapped to 14q13-q24 modulating total serum IgE levels in families with asthma.
A.H. Mansur, D.T. Bishop, S.T. Holgate, A.F. Markham and J.F.J. Morrison.
Thorax, 59, 876-882 (2004).
 304. Molecular Biology of Prostate Cancer.

- M.K. Karayi and A.F. Markham.
Prostate Cancer and Prostatic Disease, 7, 6-20 (2004).
305. Minister for a Day: Secretary of State for Health.
 A.F. Markham.
Whitehall and Westminster World/Public Service News, 14, 31-32 (2004).
 306. Enumeration and phenotypic characterisation of synovial fluid multipotential mesenchymal progenitor cells in inflammatory and degenerative arthritis.
 E.A. Jones, A. English, K. Henshaw, S.E. Kinsey, P. Emery, A.F. Markham and D. McGonagle.
Arthritis & Rheumatism, 50, 817-827 (2004).
 307. Cancer Research – a vision for the future.
 A.F. Markham.
Nature, 428, (6980) xii, (2004).
 308. Homozygosity for a missense mutation in the 67 kDa isoform of glutamate decarboxylase in a family with autosomal recessive spastic cerebral palsy: parallels with Stiff-Person Syndrome and other movement disorders.
 C.N. Lynex, I.M. Carr, J.P. Leek, R. Achuthan, S. Mitchell, E.R. Maher, C.G. Woods, D.T. Bonthron and A.F. Markham.
BMC Neurology, 4, 20-28 (2004).
 309. Obesity ideas. The bottom line.
 P. Hollins and A.F. Markham.
Health Services Journal, 114, 16-17 (2004).
 310. IL-7 deficiency and prolonged, therapy-induced lymphopenia in rheumatoid arthritis.
 F. Ponchel, R.J. Berburg, S.J. Bingham, J. Moore, A. Protheroe, S.H. Douglas, A. Masurel, U. Fearon, D.J. Veale, D. McGonagle, A.F. Markham, D. Ma., J.H. van Laar, H. Papondaki, P. Emery and J.D. Isaacs.
Arthritis Res. Therapy, 7, 80-92 (2005).
 311. Marker gene transfer into human haemopoietic stem cells using a herpesvirus saimiri-based vector.
 G.M. Doody, J.P. Leek, A.K. Bali, A. Ensser, A.F. Markham and E.A. de Wynter.
Gene Therapy, 12, 373-379 (2005).
 312. Macrophage migration inhibitory factor promotes intestinal tumorigenesis.
 J.M. Wilson, P.L. Coletta, R.J. Cuthbert, N. Scott, K.A. MacLennan, G. Hawcroft, L. Leng, J.B. Lubetsky, K.K. Jin, E. Lolis, F. Medina, J.A. Brieva, R. Poulson, A.F. Markham, R. Bucala and M.A. Hull.
Gastroenterology, 129, 1485-1503 (2005).
 313. Analysis of Fcγ receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B.
 A.W. Morgan, J.H. Barrett, B. Griffiths, D. Subramanian, J.I. Robinson, V.H. Keyte, M. Ali, E.A. Jones, R.W. Old, F. Ponchel, A.W. Boylston, R.D. Situnayake, P. Emery, A.F. Markham and J.D. Isaacs.
Arthritis Res. Therapy, 8, R5 (2005).

314. Why “satisfactory” is not good enough in cancer research.
A.F. Markham.
New Scientist, 2545, 59-60 (2006).
315. Regulation of stromal cell cyclooxygenase-2 in the ApcMin/+ mouse model of intestinal tumorigenesis.
M.A. Hull, O.O. Faluyi, C.W. Ko, S. Holwell, D.J. Scott, R.J. Cuthbert, R. Poulsom, R. Goodlad, C. Bonifer, A.F. Markham and P.L. Coletta.
Carcinogenesis, 27, 382-391 (2006).
316. Combating Cancer.
A.F. Markham.
Public Service Review: Central Government, 12, pp 154-157 (2006).
317. A family with Papillon-Lefevre syndrome reveals a requirement for Cathepsin C in granzymeB activation and NK cell cytolytic activity.
J.L. Meade, E.A. de Wynter, P. Brett, S.M. Sharif, C.G. Woods, A.F. Markham and G.P. Cook.
Blood, 107, 3665-3668 (2006).
318. Interactive visual analysis of SNP data for rapid autozygosity mapping in consanguineous families.
I.M. Carr, K. Flintoff, G.R. Taylor, A.F. Markham and D.T. Bonthron.
Human Mutation, 27, 1041-1046 (2006).
319. Human menopausal and pregnant mare serum gonadotrophins in murine superovulation regimens for transgenic applications.
D.A. Brooke, N.M. Orsi, J.F. Ainscough, S.E. Holwell, A.F. Markham and P.L. Coletta.
Theriogenology, 67, 1409-1413 (2007).
320. Sequence analysis and editing for bisulphite genomic sequencing projects.
I.M. Carr, S. Cordery, E.A. Valleley, A.F. Markham and D.T. Bonthron.
Nucleic Acids Research, 35, e79 (2007).
321. Lack of interleukin-4 receptor alpha chain-dependent signalling promotes azoxymethane-induced colorectal aberrant crypt focus formation in Balb/c mice.
C. Ko, R. Cuthbert, N. Orsi, D. Brooke, S. Perry, A.F. Markham, P.L. Coletta and M.A. Hull.
J. Pathology, 214, 603-609 (2008).
322. Not too black an outlook for Health Services Research.
A.F. Markham.
British Medical Journal, 336, 106-107 (2008).
323. Molecular analysis of sixteen unrelated Factor XIII deficient families from south eastern Iran.
C.H. Trinh, W.S. El Sayed, P. Eshyghi, E. Miri-Moghaddam, A. Zadeh-Vakili, A.F. Markham and R. Anwar.
British Journal of Haematology, 140, 581-584 (2008).
324. Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy.

- S. Uppal, C.P. Diggle, I.M. Carr, C.W.G. Fishwick, M. Ahmed, G.M. Ibrahim, P.S. Helliwell, A. Latos-Bielenska, S.E.V. Phillips, C.P. Bennett, A.F. Markham and D.T. Bonthron. Nature Genetics, **40**, 789-793 (2008).
325. Haematopoietic repopulating activity in human cord blood CD133+ quiescent cells. S.A. Boxall, G.P. Cook, D. Pearce, D. Bonnet, Y.M. El-Sherbiny, M.P. Blundell, S.J. Howe, J.P. Leek, A.F. Markham and E.A. de Wynter. Bone Marrow Transplantation, **43**, 627-635 (2009).
 326. Ketoheokinase: expression and localisation of the principal fructose-metabolising enzyme. C.P. Diggle, M. Shires, D. Leitch, D. Brooke, I.M. Carr, A.F. Markham, B.F. Hayward, A. Asipu and D.T. Bonthron. J Histochem Cytochem, **57**, 763-774 (2009).
 327. IBDfinder and SNPsetter: tools for pedigree-independent identification of autozygous regions in individuals with recessive inherited disease. I.M. Carr, E. Sheridan, B.E. Hayward, A.F. Markham and D.T. Bonthron. Human Mutation, **30**, 960-967 (2009).
 328. "Current innovations in the treatment and prevention of breast cancer": *Proceedings of the 3rd Jephcott Symposium*. H. Brauch, M. Dixon, L. Fallowfield, A. Howell, V.C. Jordan, A.F. Markham, D. Misselbrook, T. Powles, Z. Rayter, D. Roebuck, N. Wolmark, L. Weiner and R. Williamson. Royal Society of Medicine Press, April, 2009, pp 1-63.
 329. Inferring relative proportions of DNA variants from sequencing electropherograms. I.M. Carr, J.I. Robinson, R. Dimitriou, A.W. Morgan, A.F. Markham and D.T. Bonthron. Bioinformatics, **25**, 3244-3250 (2009).
 330. Shadow autozygosity mapping by linkage exclusion (SAMPLE): a simple strategy to identify the genetic basis of lethal autosomal recessive disorders. I.M. Carr, K. Szymanska, E. Sheridan, A.F. Markham, D.T. Bonthron and C.A. Johnson. Human Mutation, **30**, 1642-1649 (2009)
 331. Common and recurrent HPGD mutations in Caucasian individuals with primary hypertrophic osteoarthropathy. C.P. Diggle, I.M. Carr, E. Zitt, K. Wusik, R. Hopkin, C. Prada, O. Calabrese, O. Rittinger, M. Punaro, A.F. Markham and D.T. Bonthron. Rheumatology, **49**, 1056-1062 (2010).
 332. Mutations in TSPAN 12 cause autosomal-dominant Familial Exudative Vitreoretinopathy (FEVR). J.A. Poulter, M. Ali, D.F. Gilmour, A. Rice, H. Kondo, K. Hayashi, D.A. Mackey, L. Kearns, J.E. Craig, E.A. Pierce, L.M. Downey, M.D. Mohamed, A.F. Markham, C.F. Inglehearn and C. Toomes. American Journal of Human Genetics, **86**, 248-253 (2010).
 333. Genetic diagnosis of familial breast cancer using clonal sequencing. J.E. Morgan, I.M. Carr, E. Sheridan, C.E. Chu, B. Hayward, N. Camm, H.A. Lindsay,

- C.J. Mattocks, A.F. Markham, D.T. Bonthron and G.R. Taylor.
Human Mutation, **31**, 484-491 (2010).
334. Illuminator, a desktop program for mutation detection using short-read clonal sequencing.
I.M. Carr, J.E. Morgan, E.E. Sheridan, A.F. Markham, G.R. Taylor and D.T. Bonthron.
Clinical Chemistry, in press (2010).
 335. GeneScreen: a program for high-throughput mutation detection in DNA sequence electropherograms
I.M. Carr, G.R. Taylor, R. Charlton, S. Ellard, E.E. Sheridan, A.F. Markham and D.T. Bonthron.
Journal of Medical Genetics, in press (2010).
 336. MethylViewer: computational analysis and editing for bisulphite sequencing and Methyltransferase Accessibility Protocol for Individual Templates (MAPit) projects.
C.E. Pardo, I.M. Carr, C.J. Hoffman, R.P. Darst, A.F. Markham, D.T. Bonthron and M.P. Kladde.
Nucleic Acids Research, in press (2010).
 337. Both isoforms of ketohexokinase are dispensable for normal growth and development.
C.P. Diggle, M. Shires, C. McRae, D. Crellin, J. Fisher, I.M. Carr, A.F. Markham, B. Hayward, A. Asipu and D.T. Bonthron.
Physiological Genomics, in press (2010).

PATENT APPLICATIONS

1. Genetically Modified Microorganisms expressing Interferon.
K.T. Atherton, E. de Maeyer, M.D. Edge, A.F. Markham, P.A. Meacock and J.D. Windass.
UK Patent Application Nos. 8109678, 8109919, 8112446, 8126967.
European Patent No. 62971.
2. A method for detecting the presence or absence of a plurality of variant sequences in a single test and kits therefore.
A.F. Markham and C.R. Newton.
UK Patent Application No. 8711688
3. Method of Detecting Nucleotide Sequences.
C.R. Newton and A.F. Markham.
UK Patent Application Nos. 8805692 and 8814170.
4. Therapeutic Agents.
A.F. Markham.
UK Patent Application No. 8805808.
5. Variant Nucleotides.
A.F. Markham, S.J. Powell, C.R. Newton and A. Graham.
UK Patent Application No. 8920009.1.
6. Amplification Processes (ARMS).
C.R. Newton and A.F. Markham.

- UK Patent Application No. 8920097.6. (EP332435)
7. Hybridisation Probes.
C.R. Newton and A.F. Markham.
UK Patent Specification No. 8925898.2. (GB2225112)
 8. A method for the amplification of nucleotide sequences.
A.F. Markham, J.C. Smith and R. Anwar.
UK Patent Application No. 8917143.3. (GB2221909)
European Patent Publication No. 356021.
 9. Diagnostic Method.
A.F. Markham, J.C. Smith, R. Anand, D. Ogilvie, R. Anwar, J.H. Riley and P. Elvin.
UK Patent Application No. 8920211.3.
European Patent Publication No. 416801.
 10. Method of Diagnosis.
A.F. Markham, J.C. Smith and P. Hedge.
UK Patent Application No. 8920210.5.
 11. Amplification Methods.
A.F. Markham, C.G. Copley, W.L. McPheat, J.C. Smith and R. Anwar.
UK Patent Application No. 9101373.0. (EP439330)
 12. Polynucleotide.
A.F. Markham and P.J. Hedge.
UK Patent Application No. 9100975.3.
 13. Nucleic Acid.
A.F. Markham and P.J. Hedge.
UK Patent Application No. 9100963.9.
 14. Polynucleotides.
A.F. Markham and P.J. Hedge.
UK Patent Application No. 9100962.1.
 15. Gene for Familial Polyposis.
R.L. White, J. Groden, G. Joslyn, A. Thliveris, M. Carlson, H. Albertsen, K. Kinzler, Y. Nakamura, B. Vogelstein and A.F. Markham.
WPC Application (USA) 6114124.
 16. Inherited and Somatic Mutations of APC Gene in Colorectal Cancer of Humans.
H. Albertsen, R. Anand, M. Carlson, J. Groden, P. Hedge, G. Joslyn, K. Kinzler, A. Markham, Y. Nakamura, A. Thlivens, B. Vogelstein and R. White.
US Patent No. 5783666.
 17. Diagnosis and Treatment of Degenerative Disease.
A.F. Markham and P.A. Robinson.
UK Patent Application No. 9406577.8.
 18. Sorbitol Metabolism and Disease.
A.F. Markham and I.M. Carr.

UK Patent Application No. GB 94/12964.0.

19. Genetic Basis of Factor XIII Activity.
R. Anwar, K.J.A. Miloszewski and A.F. Markham.
Patent No. W09617953.
20. MODY - Type 2 Diabetes.
D.T. Bonthron and A.F. Markham.
UK Patent Application No. GB 95/12574.6
US Patent Application No. US 08/493008
21. Gorlin Syndrome.
N.J. Lench, P.A. Robinson and A.F. Markham.
UK Patent Application No. GB 95/12578.7
22. Polypeptide with mismatch nucleotide binding activity.
A. Whitehouse, D.M. Meredith and A.F. Markham.
Patent No. WO9715657.
23. New ubiquitin conjugating enzymes and corresponding DNA.
A.F. Markham and P.A. Robinson.
Patent No. 9527066.
24. Use of pancreatic REG gene product, lithostathine.
P.J. Guillou and A.F. Markham.
Patent No. WO9899561.
25. Herpesvirus saimiri variants useful as vectors for gene therapy.
A.F. Markham and D.M. Meredith.
Patent No. WO9810083.
26. New equine herpes virus vectors.
A.F. Markham and D.M. Meredith.
Patent No. WO9827216.
27. Treatment of tumours.
A.F. Markham and D.M. Meredith.
Patent No. WO9837905.
28. Novel polypeptides to treat clinical conditions resulting from UBC7-mediated protein degradation.
A.F. Markham and P.A. Robinson.
Patent No. WO9950421.
29. Assay for detecting predisposition or aggressive nature of gastrointestinal cancer.
P.J. Guillou and A.F. Markham.
Patent No. WO200001847.
30. New nucleic acid encoding a ubiquitin conjugating enzyme associated protein.
A.F. Markham and P.A. Robinson.

Patent No. WO200032787.

31. Herpesvirus saimiri vector comprising a gene encoding an envelope protein of HIV, useful as a vaccine.
A.F. Markham and D.M. Meredith.
Patent No. WO200032802.
32. New human and mouse nucleic acids encoding a tissue repair protein.
D.T. Bonthron and A.F. Markham.
Patent No. WO200040719.
33. Novel nucleic acid encoding a promoter derived from Herpesvirus saimiri.
A.F. Markham and A. Whitehouse.
Patent No. WO200049167.
34. Novel nucleic acids encoding a protein whose absence is associated with oral and other cancers.
A.P. Jackson and A.F. Markham.
Patent No. WO200190354.

